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ABSTRACT OF THE DISSERTATION
Leishmania parasites are the causative agent of leishmaniasis, a neglected tropical
disease. An important aspect of Leishmania biology is asymptomatic parasite persistence,
which typically occurs after clinical cure. Persistent parasites remain enigmatic despite
their importance as reservoirs for transmission, having roles in maintaining protective
immunity, and posing the risk of reactivation. I developed methods for assessing parasite
replication by BrdU labeling and showed that persistently infected mice harbor two subpopulations of L. major, one labeling similarly to acute-phase parasites, with the other
showing much less labeling. That persistent parasite replication occurs without a
commensurate increase in parasite number implies parasite killing. Continual parasite
replication and destruction within antigen presenting cells provides an attractive model
explaining the role of persistent parasites in maintaining immunity, namely through
constant presentation of antigens derived from dead parasites and subsequent immune
boost. While many of the persistent parasites are within host cells expressing high levels
of iNOS, there is no apparent correlation between this and the parasite’s
survival/replication status. Attenuated lpg2- L. major, a proposed model of parasite
persistence, resemble WT persistent parasites for most parameters tested. However, more
lpg2- parasites are associated with host cells expressing elevated levels of arginase 1,
which further studies implicate as a negative correlate of immunity. While persistent
parasites immunize their hosts against pathology from subsequent infection, experiments
using marked parasites showed that persistently infected mice could be super-infected.
This has implications for the generation of parasite phenotypic diversity, as genetically
distinct parasites could be simultaneously transmitted to sand flies, the site of parasite

ii

sexual recombination. In addition to my studies of Leishmania persistence, I also
identified markers that differentiate amastigote- from metacyclic-stage parasites, and
used them to assay parasite differentiation within different host cell types in vitro.
Although the markers were induced in the same sequence in all host cell types, the
parasites in bone marrow-derived macrophages and dendritic cells were slower to lose
LPG expression and resume replication. These data show that invading L. major can
retain virulence factors, potentially playing a role in situations where parasites are
transferred from one host cell to another.
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Chapter 1

Introduction

This chapter was written entirely by M. Mandell.

1

Leishmaniasis, a neglected tropical disease
‘Neglected diseases’ are defined as diseases that are not major focuses of the
pharmaceutical industry despite great global demand for improved treatments and/or
vaccines (1). The spectrum of diseases caused by infection with protozoan parasites of
the genus Leishmania, collectively referred to as leishmaniasis, is a prime example of
such a disease. Leishmaniasis is common throughout tropical, sub-tropical, and temperate
regions of the Americas, Europe, Asia, and Africa, with an estimated 12 million people
infected and more than 350 million people at risk (2). However, as the overwhelming
majority of cases are amongst the very poor in the developing world, there is little profit
motive for the development of new cures or preventative measures.
The clinical manifestations of leishmaniasis are quite diverse, with different species of
Leishmania or even by different isolates of the same Leishmania species causing
drastically different pathologies (2). In general, there are three classifications of disease
manifestations. The first is cutaneous leishmaniasis (CL), which is defined by non-life
threatening skin lesions of varying severity. One species which causes CL is Leishmania
major, the organism that is the focus of my work. The second major type of leishmaniasis
is muco-cutaneous disease (MCL), which is the prevalent form of the disease in some
parts of Latin America. MCL patients present first with a skin lesion at the site of
Leishmania infection, but eventually develop lesions of the mucus membranes of the face
that are very severe and disfiguring despite the fact that very few parasites are found in
those lesions (2). The third disease manifestation is visceral leishmaniasis, in which
parasites of L. donovani or L. infantum disseminate to the spleen and liver of infected
patients and there replicate to high titers, resulting in disease that is fatal if untreated (2).
2

Perhaps a fourth classification of leishmaniasis could be “asymptomatic leishmaniasis” as
most human infections with Leishmania result in asymptomatic persistent infections that
last for the rest of the patient’s life (2). Although such infections may actually be
beneficial under normal circumstances by conferring protective immunity against
subsequent Leishmania infections (3), they pose a substantial risk of reactivation
resulting in severe disease in the event that the patient becomes immunosuppressed (4).
Reactivation has become a serious problem as the prevalence of HIV/AIDS has increased
in regions in which leishmaniasis is common (5).
Vaccines and treatments for leishmaniasis
There is currently no vaccine to prevent leishmaniasis caused by any Leishmania species
(2). However, there is reason to hope that the development of such a vaccine might be
possible, as CL patients with healed lesions are protected against pathology from
subsequent infections (3). This knowledge is the basis for the centuries-old practice of
leishmanization, in which live virulent parasites are intentionally infected into an
inconspicuous site on the body such as the buttocks to protect against pathology in a
more visible site. To date, many different vaccination approaches (e.g. live-attenuated
parasites, recombinant parasite proteins, etc.) have been tried in a laboratory setting with
varying success (6, 7).
Several drugs are available to treat leishmaniasis, but all have serious drawbacks. The
first drugs used against leishmaniasis are based on pentavalent antimony, and have been
in use since the early 20th century. While reasonably inexpensive, antimony-based
treatments are associated with serious side effects including death, and have lost efficacy
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as the parasites in several parts of the world, especially India, have developed resistance
(8). Other drugs available include miltefosine and liposomal amphotericin B. Miltefosine
is associated with severe gastrointestinal side effects and teratogenicity and its efficacy is
highly dependent on the Leishmania species/strain infecting the patient (2). Liposomal
amphotericin B is a highly effective anti-parasitic agent, but is associated with serious
side-effects and its cost is beyond the reach of most of the patients who are likely to need
it (2). Because of these challenges, there remains great need for new treatment options.
Overview of the Leishmania life cycle
Leishmania parasites alternately infect sand fly and vertebrate hosts with transmission
taking place as a result of the sand fly taking a blood-meal (Figure 1-1). Once in the sand
fly, the parasites differentiate into the procyclic promastigote stage, which have relatively
long flagella and express the multifunctional virulence factor lipophosphoglycan (LPG)
on their surface. LPG mediates attachment of these parasites to the sand fly midgut,
preventing their excretion (9). Over the course of the next 10-14 days, the parasites
replicate, undergo several developmental changes, detach from the midgut, and finally
enter a G1 cell cycle arrest, becoming metacyclic promastigotes (10). Metacyclic-stage
parasites are considered the transmissible form of the life-cycle, and consistent with this
role, these parasites express virulence factors important for the establishment phase of
vertebrate infection and are found within the mouth parts of the sand fly awaiting the next
blood-meal (10). These parasites are then taken up by phagocytic immune cells and are
eventually found within fusogenic phagolysosomes of macrophages, in which they
replicate as amastigote-stage parasites. Amastigotes differ from metacyclics in several
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ways, both in terms of their gene expression and morphology. Relative to metacyclics
and other promastigotes, amastigotes are rounder and have much shorter flagella.
In many “textbook” versions of the Leishmania life cycle, metacyclic-stage parasites are
depicted as interacting exclusively with macrophages, and as such, most studies of the
roles of Leishmania virulence factors have focused on macrophages. In reality, however,
this is likely an over-simplification and parasites deposited into a host encounter several
different host cell types in addition to macrophages, thus complicating the typical
reductionist in vitro studies and raising questions as to their relevance to biology. In
particular, neutrophils (PMNs) and dendritic cells (DCs) have been shown by two-photon
microscopy studies to infiltrate the site of parasite inoculation within a few hours after
infection, where they engulf the parasites (11-13). Interactions between metacyclics and
these cell types may in fact predominate over metacyclic-macrophage interactions,
necessitating a re-evaluation of the textbook description of the parasite life cycle and new
studies of the virulence factors required for survival within and/or parasitism of PMNs
and DCs.
Although many or most parasites are found within PMNs and DCs shortly after
inoculation, by 48 hours after infection most parasites at the inoculation site are found
within macrophages (12). There are a number of models that could explain how this
transfer occurs. One possibility is that the parasites within PMNs and DCs die and are
cleared, leaving only those parasites that infected macrophages at 48 hours after
infection. However, substantial evidence suggests that this is not the case as several in
vitro studies have demonstrated parasite survival within PMNs and DCs, and the transfer
of parasite-loaded PMNs into a naïve mouse yields a lesion comparable to the inoculation
5

of an equal number of free parasites (12, 14-17). Another possibility that is probably
more relevant for DCs than for PMNs is that infected DCs could leave the inoculation
site and migrate to the regional lymph node, resulting in infection of that tissue and
leaving infected PMNs or macrophages at the infection site (11).
A third model is that the parasites infect PMNs/DCs first and are subsequently transferred
from these cells to macrophages. Under this scenario, the parasites could enter
macrophages in one of two ways. The first involves the release of the parasite from an
infected DC/PMN, and then the free parasite is engulfed by a macrophage. Consistent
with this, two-photon microscopy studies identified instances in which infected PMNs
appeared to die, releasing an intact parasite that appeared to then be taken up by another
cell (12). While this sounds similar to what likely happens with amastigote-infected
macrophages in which after several rounds of parasite replication the macrophage bursts
releasing amastigotes that can then infect new macrophages, it is important to note that at
48 hours after infection the parasites are unlikely to have had sufficient time to undergo
substantial replication.
The other way in which sequential infection could take place is by the macrophage
engulfing the infected PMN/DC in what is referred to as the “Trojan horse” model of
infection (16, 18). This model primarily deals with PMNs, which are very short-lived
cells and that typically die by apoptosis. In this model, metacyclic-stage parasites enter
PMNs and survive, even though their host cells ultimately undergo apoptosis.
Macrophages are then recruited to the site of infection to clear the apoptotic PMNs, many
of which contain viable parasites. Phosphatidyl serine on the surface of the infected
apoptotic PMNs induces the macrophages to adopt a deactivated phenotype, thus
6

allowing safe entry for the parasite into its “preferred” host cell (18). Despite much effort,
L. major entry into macrophages within PMN “Trojan horses” has not been observed in
vivo (12, 13). However, macrophages have been observed to phagocytose apoptotic PMN
that contain apparently intact Leishmania in vitro (14, 16).
Regardless of the manner of parasite transfer from the first cell type infected to
macrophages, one important question is whether the parasite undergoes differentiation
within the host cell types that it encounters first and what stage of the parasite life cycle
(metacyclic or amastigote) is encountered by the macrophage. This question has
relevance for a number of temporally regulated virulence factors, including LPG, GP63
and GP46, which are known to be important in the establishment-phase of mouse
infections but are not expressed on amastigotes (19-23). If most parasites enter
DCs/PMNs and differentiate into amastigotes prior to encountering macrophages, then
macrophages would rarely encounter these virulence factors in vivo, and it is likely that
they have evolved for interactions with other cell types. Alternatively, the parasites may
retain the expression of these virulence factors as they transit through these cells allowing
for the virulence factors to subsequently impact their interactions with macrophages.
To date, the only data regarding the ability of the parasites to differentiate into the
amastigote stage within non-macrophage host cells comes from studies of infected
neutrophils, in which at least some of the parasites appear to remain in the metacyclic
stage for up to 42 hours post-infection as assessed by retaining long, motile flagella (16).
This study, however, made no mention of the percent of parasites with long flagella nor
addressed other changes associated with differentiation such as the loss of promastigotespecific virulence factors. In Chapter 2, I address whether L. major metacyclic-stage
7

parasites differentiate within dendritic cells, one of the other first cell types to encounter
invading parasites, and for how long they retain the expression of the early virulence
factor LPG. As part of these studies, I characterized five markers that are differentially
expressed between amastigotes and metacyclics. Two of these were amastigote-specific
antigens that are recognized by monoclonal antisera that were first generated by Charles
Jaffe (24). The localization pattern of both of those antisera was particularly interesting,
and is detailed in Appendix I.
Leishmania major infections in mice
The typical course of L. major infection in susceptible and resistant mice strains is shown
in Figure 1-2. Following a either sand fly vector-mediated infection or needle inoculation
of mice, L. major parasites replicate rapidly for several weeks in the absence of overt
pathology in what is referred to as the ‘silent phase’ of the infection (25, 26). During this
phase of the infection, the leishmaniasis-promoting IL-4 is the predominant cytokine
produced by infection site-derived cells (25). In ‘susceptible’ BALB/c mice, IL-4
production is maintained throughout the infection, resulting in Th2 polarization and,
ultimately, fatal leishmaniasis (27). In contrast, in ‘resistant’ strains of mice such as
C57BL/6, cells derived from the infection site begin to express the Th1 cytokines IL-12
and interferon-γ co-incident with the inception of lesion pathology (4-5 weeks postinfection) (25, 27). Ultimately, Th1-cytokine producing cells overwhelm IL-4 producing
cells, leading to infected macrophages adopting a “classically activated” phenotype,
which involves the expression of iNOS and subsequent generation of nitric oxide, a
molecule that is essential for the control of Leishmania infection in mice (28-32). As a
result, parasite number declines and the lesions eventually resolve ~12 weeks post8

infection (26). Healed mice are then protected against pathology from subsequent L.
major infections (33).
Interestingly, despite the absence of pathology and the presence of this strong protective
immune response, healed hosts continue to harbor a small, roughly constant number of
viable parasites for the remainder of their life (34). These persistent parasites are
important for several reasons. First, despite their limited numbers (~100 - 1000 in mice)
(25, 35, 36) persistent parasites can still be transmitted to sand fly vectors, and as such,
are a reservoir for the pathogen (26, 37). Second, as is the case with infected people, the
parasites in persistently infected mice can “reactivate” in the event of
immunosuppression, leading to severe disease (4, 29). Finally, they may be beneficial to
hosts with intact immune systems because they help maintain protective immunity
against pathology from subsequent Leishmania infections (38). In fact, treatment of
persistently infected mice to achieve a sterile cure renders those mice susceptible to new
infections (36). As described below, the focus of Chapters 3 and 4 is to better understand
the biology of these persistent parasites.
The biology of L. major persistence
Asymptomatic persistence of Leishmania in their hosts, either in experimentally infected
mice or in human patients, is a far more common result than sterile cure (34). Such
infections are characterized by low parasite titers, the lack of pathology, and protective
immunity against subsequent the pathology from infections. In fact, it is possible that the
entry of the parasites into an asymptomatic persistent state may in fact be advantageous
to the parasites, as they can still be transmitted from persistently infected hosts to new
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sand flies (26, 39). Supporting this, when L. tropica parasites are transmitted by sand flies
to their natural rodent hosts, these parasites directly enter a persistence-like state without
inducing pathology (39).
Despite their importance, both medically and in terms parasite biology, very little is
known about persistent Leishmania, perhaps resulting from the fact that no in vitro model
exists, and from the challenges associated with studying persistence in vivo (e.g. long
infection times and low parasite numbers). On important unknown is whether or not
persistent L. major replicate, as the number of persistent L. major remains relatively
constant for the lifespan of its host (35, 40). Two models could explain this constant
parasite population. One possibility is that the persistent parasites could be in a quiescent
state that resists killing by the host. Alternatively, the parasites could replicate as in the
acute phase, but their numbers do not increase as any replication is offset by parasite
destruction. This second model is particularly attractive as it may help explain the
requirement of persistent parasites to maintain immunity: constant presentation of
antigens from killed parasites would serve to maintain the effector T cell population
necessary for anti-Leishmanial immunity (41). Thus, a crucial question that I address in
chapter 3 is whether or not persistent parasites replicate.
It is clear from both clinical and laboratory studies that the host’s immune system is
responsible for maintaining the parasites in an asymptomatic persistent state. Similar to
what is seen when infected persons become immunosuppressed as a result of HIV/AIDS,
persistent infections ‘reactivate’ in mice treated with inhibitors of iNOS or interferon-γ
signaling, or in which CD4+ T cells have been depleted (29).
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Although the host’s immune response clearly is involved in preventing the reactivation of
persistent parasites, the parasites appear to be able to prevent it from completely clearing
the infection. Two non-exclusive models have been proposed to explain how why sterile
cure is not achieved. The first model to explain how Leishmania persist despite their
host’s protective immunity against disease pathology is based on the finding that the
immunomodulatory cytokine IL-10, along with immunosuppressive CD4+CD25+
regulatory T cells (Treg), are important for maintaining persistent infections, and that the
blockade of IL-10 signaling or Treg depletion results in sterile cure of L. major-infected
mice (36, 42, 43). IL-10 and Tregs are thought to facilitate parasite persistence by
preventing host cell activation and iNOS expression, thus providing a safe niche in which
the parasites can survive (36).
The second model is referred to as the “safe-cell” model (44). This model is based on the
observation that the majority of L. major-infected iNOS-negative cells in persistently
infected lymph nodes express fibroblast, but not macrophage, markers. In contrast,
almost all infected macrophages from the same persistently infected tissue expressed
iNOS (44). As the nitric oxide produced in iNOS-positive cells is lethal to Leishmania
(29), it was proposed that these cells are sites of parasite destruction, while the fibroblasts
are “safe cells” in which the parasites survive (44). Another candidate “safe cell” is the
alternatively activated macrophage. These cells have been shown to support enhanced
replication of L. major in vitro and in vivo as a result of their expression of arginase-I,
which simultaneously blocks the formation of leishmanicidal NO while generating
polyamines that the parasites can use for growth (45-47). Since first being proposed by
Bogdan et al. in 2000 (44), the safe cell model has been cited 87 times, but neither the
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study’s findings nor the proposed model have been independently tested. Thus one of the
aims of chapter 3 is to test the safe cell model. One assumption of the model is that
parasites should be found in safe cells such as fibroblasts or alternatively activated
macrophages at all sites of persistence (i.e. the inoculation site and the draining lymph
node). As Bogdan’s study focused exclusively on parasites within lymph node tissue, I
sought to determine what types of host cells were infected at the footpad inoculation site
to see if infection of proposed safe cells occurred at that site as well. Another assumption
of the safe cell model is that iNOS-expressing macrophages are an unsafe cell in which
persistent parasites would be killed. I therefore asked whether this assumption was
correct or whether persistent parasites could survive within iNOS-expressing host cells.
As mentioned above, persistent parasites are difficult to study, at least in part due to the
long infection periods required to establish a persistent infection in mice. Interestingly,
several parasite lines (including parasites lacking fructose-1,6-bisphosphatase or the
nucleotide sugar transporter LPG2) have been generated that appear to directly enter a
persistent-like state without first inducing pathology, suggesting that the parasite genes
required for persistence differ from those required for virulence (35, 48). The LPG2 gene
encodes a protein Golgi-localized GDP-mannose transporter which is involved in the
synthesis of parasite virulence factors including phosphoglycans. Despite their long-term
persistence in mice, these parasites appear incapable of replicating to high numbers and
causing disease, as they are asymptomatic even in immunodeficient mice or in mice
lacking iNOS (35). Nevertheless, they resemble WT persistent parasites in the number of
viable parasites recoverable from infected mice and in the fact that lpg2- parasites are
capable of generating and maintaining protective immunity against subsequent L. major
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infections in some strains of mice (35, 49, 50). For these reasons, lpg2- and other “persist
without pathology” parasites may be valuable both as models of Leishmania persistence
and have potential as live-attenuated vaccine candidates if they resemble persistent wild
type parasites (35). A final aim of the data presented in chapter 3 is to compare the
replication and localization of lpg2- parasites in mice with what is seen with persistent
wild type parasites.
Leishmania, concomitant immunity, and evolution
Because infected hosts are usually capable of developing an appropriate immune
response, infection with Leishmania major is rarely fatal (51). Instead, mammalian hosts
typically control the infection and heal. At the same time, while still harboring persistent
parasites, they become protected against pathology from subsequent Leishmania
infections: a condition known as concomitant immunity or premunition (52-54).
Although the benefits to the host resulting from an effective anti-Leishmania immune
response and subsequent immunity are obvious, there are likely also benefits to the
parasite. One such benefit comes as a consequence of parasite persistence within a
healthy host: the longer the host survives, the better the chances that the parasite will be
transmitted (55-57).
The term “concomitant immunity” is most commonly used in reference to infections with
parasitic worms such as Schistostoma mansoni, where excrement from adult worms
contains antigens that promote protective immunity against juvenile worms, which are
the infectious forms of the worm’s life cycle. The adult worms are thought to benefit
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from vaccinating their host against super-infection by eliminating intraspecific
competition (52, 58).
Another potential benefit to the pathogen comes if the host’s immune response is
sufficiently strong to prevent super-infection, thus gaining for the first pathogen to infect
the host exclusive transmission rights for its genome. A pathogen capable of such
exclusive infection would have a strong selective advantage over those that could not,
and the ability to generate exclusivity would likely spread quickly through a population,
as has been proposed for lysogenic bacteriophage (59).
In Chapter 4, I address whether the immunity maintained by persistent L. major is
capable of generating ‘exclusivity’, or in other words, if the immunity maintained by
persistent L. major is strong enough to prevent super-infecting parasites to establish their
own persistent infections. In addition to being an important evolutionary question, this
question has relevance for understanding the development and maintenance of
Leishmania phenotypic diversity, as sterilizing immunity to re-infection would greatly
diminish the chances of an infected host to pass on a mixed infection to a sand fly where
parasite sexual recombination could take place (60).
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Figure legends
Figure 1-1. The Leishmania life cycle. A. Sand flies are infected after taking a bloodmeal from an infected host. The parasites differentiate into procyclic promastigotes,
which are retained in the sand fly’s midgut via interactions between parasite LPG and
receptors on the sand fly’s intestinal epithelium. B. Parasites eventually detach from the
midgut and develop into infectious metacyclic-stage parasites, which are found in the
mouthparts of the sand fly awaiting the next blood-meal. C. Metacyclic-stage parasites
are deposited into the dermis of their mammalian host, where they interact with several
different types of host cells including macrophage, dendritic cells, and neutrophils. D.
Ultimately, parasites are found as amastigote forms in acidified phagolysosomes of
macrophages. E. Parasites replicate within phagolysosomes eventually resulting in the
lysis of the macrophage and the release of amastigotes which can either go on to infect
new macrophages or be ingested by a biting sand fly, completing the cycle.
Figure 1-2. The course of L. major infection in susceptible and resistant mouse strains.
Both graphs. Black lines represent parasite number, grey lines represent lesion pathology.
Parasite numbers increase dramatically during the first ~4 weeks after infection in the
absence of pathology in what is termed the ‘silent phase’ of infection. Top graph.
Infection of ‘susceptible’ BALB/c mice results in Th2 skewing associated with
uncontrolled parasite growth and eventually fatal leishmaniasis. Bottom graph. Infection
of ‘resistant’ C57BL/6 mice results in Th1 skewing, associated with lesion healing and a
decrease in parasite number starting 6-8 weeks post infection. Lesions typically heal 1215 weeks after infection. Healed mice are immune to subsequent L. major infections and
continue to harbor ~1000 parasites for the remainder of their lives (persistent phase).
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Abstract
Many workers have proposed that neutrophils and dendritic cells (DCs) are the
predominant cell types first engulfing Leishmania following the transmission of
metacyclic parasites by a sand fly bite. Following entry into such ‘transit’ cells, parasites
are ultimately transferred to the macrophage, although some parasites likely enter
macrophages directly as well. This raises the question as to whether parasite virulence
determinants whose functional roles are restricted to the earliest phases of establishment
of Leishmania infection persist long enough in transit to play significant roles in the
macrophage. One of such early-acting virulence factors include the most abundant
parasite surface molecule, lipophosphoglycan (LPG). We first identified a set of
experimental ‘landmarks’ that clearly differentiate infective metacyclic promastigotes
from replicating macrophage amastigotes; these markers show an orderly transition postinfection, allowing the tempo and properties of parasite differentiation to be visualized
microscopically. In peritoneal macrophages, loss of promastigote flagella and expression
of amastigote differentiation markers occurs within 12 hr, followed by entry into the cell
cycle as assessed by BrdU incorporation after 24 hr. LPG levels declined such that by 48
hr it was undetectable on most parasites. Bone marrow derived macrophages or DCs
maintained a similar sequence of marker transitions, but with different kinetics for some
but not all markers, and with fewer parasites showing evidence of replication even by 72
hr, suggesting overall a slower rate of differentiation to amastigotes. Notably LPG was
lost much less rapidly in both DC and BMM, maintaining levels as high as that seen in
metacyclics in 37% percent of the parasites after 72 hr, well beyond estimates of the
‘transit’ time to macrophages. While these LPG+ parasites have not re-entered the cell,
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they otherwise resemble amastigotes and therefore present an intermediate phenotype.
These data suggest that LPG and potentially other ‘early’ virulence factors would have
the opportunity to impact macrophage function through either the transit or direct route,
potentially facilitating parasite establishment.
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Introduction
Leishmaniasis, caused by protozoan parasites of the genus Leishmania, is considered a
neglected tropical disease because there is a lack of good treatment options despite many
millions of people at risk of infection (1). Leishmania parasites are transmitted to their
mammalian hosts by the bite of an infected sand fly which deposits non-replicating,
flagellated metacyclic-stage parasites into the dermis while taking a blood meal. Once in
the dermis, the parasites interact with phagocytic cells of the immune system, and are
eventually found within lyososome-like vacuoles in macrophages where they replicate
intracellularly as non-motile amastigotes.
Although many in vitro studies have focused on interactions of infectious parasites with
macrophages, recent in vivo data suggest that other cell types, in addition to
macrophages, also encounter and engulf invading metacyclic-stage parasites. These
include neutrophils and dendritic cells (DCs), which are rapidly recruited to the infection
site and collectively may predominate over macrophages as the first host cells for
Leishmania (2, 3). However, by 24-48 hours after infection, the percentage of L. major
within these cell types declines, such that at later time points macrophages are the
predominant cell type infected (2-4). How this transfer of the parasite from the first cell
type infected to macrophages is under debate, but presumably parasites are either
released from the infected cell and subsequently taken up by a macrophage or,
alternatively, the infected cell itself is engulfed by a macrophage (5).
Regardless of the manner of parasite transfer, an important question is whether the
parasite undergoes differentiation within its cells of first contact and what stage of the
parasite life cycle (metacyclic or amastigote) is encountered by the ‘destination’

31

macrophage. The answers to these questions could have profound consequences to our
understanding of the role of parasite virulence factors, especially those known to function
early in the initial stages of establishment of intracellular parasitism. A number of
parasite virulence factors such as lipophosphoglycan (LPG), GP63, and GP46 are
temporally regulated and not expressed by amastigotes despite having important roles in
the establishment of infection by metacyclic-stage parasites (6-10). Thus, invading
metacyclic-stage parasites could be taken up by ‘transit’ host cells such as neutrophils
and/or DCs, undergo differentiation and cease expression of these ‘early’ virulence
factors prior to their transfer into macrophages. Under this scenario, macrophages would
not encounter ‘early’ virulence factors in natural infections. Alternatively, the parasites
could retain expression of the ‘early’ virulence factors throughout the transit period until
they reach a macrophage, thus retaining the armamentarium of virulence factors for
deployment within the macrophage. Virulence factor retention could be mediated by a
variety of mechanisms, for example specific control of early virulence factor expression
or more global mechanisms such as delayed or even arrested differentiation in the transit
PMN/DC.
As an example of an ‘early’ virulence factor, we focused on the surface promastigote
glycoconjugate, lipophosphoglycan (LPG). LPG is the most abundant molecule on the
surface of invading metacyclic-stage parasites (6). Experiments with geneticallymodified Leishmania lacking genes essential for LPG synthesis have demonstrated that
LPG plays key roles in parasite survival upon infection of macrophages, including
prevention of lysis by complement, protection against oxidants, and transiently inhibiting
phagolysosomal fusion (7-10). In addition, LPG has been shown to be important in
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protecting L. donovani parasites from killing by neutrophil extracellular traps (11), and in
establishing a safe niche for these parasites facilitating their survival within neutrophils
(12).
To address the question of whether L. major metacyclics differentiate into amastigotes
within the cells types of ‘first contact’ and how long the expression of LPG is retained as
the parasites transit through these cells, we identified a set of markers suitable for
immunofluorescence microscopy that would allow an assessment of the differentiation
status of Leishmania following host cell uptake. These included markers expressed by
metacyclic promastigotes but not amastigotes such as the flagellum, employing
paraflagellar rod proteins (13), and markers expressed by amastigotes but not metacyclic
promastigotes (unknown antigens recognized by antisera T17 or T18) (14), activation of
amastigote gene expression (SSU:YFP), and replication (BrdU incorporation). We
compared the expression of these markers in peritoneal and bone marrow macrophages
(BMMs) first, in order to establish a baseline for macrophage differentiation. For these
studies, peritoneal macrophages (PEMs) serve as our gold-standard host cell because
parasites are known to enter these cells and become replicating amastigotes by 72 hours
post-infection (7, 15, 16). We then studied the expression of the stage-specific markers in
dendritic cells, one of the first cell types to be infected in vivo (2). In all three cell types,
we found that the markers of ‘amastigotigenesis’ were induced in the same order, with
amastigote marker induction occurring prior to the onset of parasite DNA synthesis. We
then used similar approaches to assess LPG level, and showed that even after 72 hr within
DCs a high fraction of intracellular parasites retained high levels of LPG. As this is well
beyond the estimated transit time of Leishmania through DCs in the literature (~24 hr),
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these data establish that the destination macrophages will encounter a significant number
of Leishmania retaining LPG at biologically relevant levels able to mediate virulence
functions characterized previously in macrophages.
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Materials and Methods
Parasite strains and culture
L. major Friedlin V1 strain (MHOM/IL/80/Friedlin; abbreviated as LmjF) parasites were
grown at 26˚C in M199 medium (US Biologicals) supplemented with 40 mM 4-(2hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES) pH 7.4, 50 μM adenosine,
1 μg ml−1 biotin, 5 μg ml−1 hemin, 2 μg ml−1 biopterin and 10% (v/v) heat-inactivated
fetal calf serum (17), in some cases containing selective drugs. LmjF parasites expressing
YFP (yellow fluorescent protein; SSU:IR1PHLEO-YFP) were described elsewhere (18).
L. major LV39cl5 lpg1- were described previously and (19) were cultured in the above
media supplemented with 2 mM L-glutamine, 9 µg ml-1 folate and RPMI Vitamin Mix
(Sigma). Infective metacyclic-stage parasites were recovered using the density gradient
centrifugation method (20). Prior to infection of host cells, purified metacyclic-stage
parasites were opsonized with serum from C5-deficient mice.
Mammalian host cells
Cells were isolated from female C57Bl/6J mice (6-10 weeks old; Jackson Labs).
Peritoneal macrophages (PEMs) were elicited by a peritoneal injection of potato starch
and harvested and maintained in DMEM (Invitrogen) containing 10% FCS and 2 mM Lglutamine as described (21). Bone marrow-derived macrophages (BMMs) and dendritic
cells (DCs) were harvested as describe previously (22). Briefly, bone marrow was flushed
from the femurs of mice and cultured in dendritic cell or macrophage growth media at
37˚ for 6 days. DCs were cultured in RPMI media without L-glutamine (Gibco)
supplemented with 10% fetal calf serum (Hyclone), Glutamax (Gibco), Na pyruvate, nonessential amino acids, and kanamycin (DC media) with the addition of 2% GM-CSF.
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BMMs were cultured in DMEM (Gibco) supplemented with 10% fetal calf serum, 5%
horse serum, Glutamax (Gibco), Na pyruvate, non-essential amino acids, and kanamycin
(as described above for the macrophage media) with the addition of 30% L-cell media as
the source of M-CSF. For infections, cells were cultured in DC or macrophage media
without growth factors. Prior to infection, PEMs, DCs, and BMMs were adhered to
sterile glass coverslips in 24 well dishes overnight.
Infection of host cells
Parasites were added to host cells at a ratio of 5:1. Typically, extracellular parasites were
removed by extensive washing 2 hours after parasites were added to host cells. Infected
cells were maintained in the media described above, which was changed daily for the
duration of the experiments. For DNA labeling studies, containing 0.1 mM 5-bromo-2'deoxyuridine (BrdU; Sigma) or 0.1 mM 5-ethynyl-2’-deoxyuridine (EdU; Life
Technologies) was added for the duration of time indicated in the text.
Antibodies
L. major nuclei were detected with a pool of rabbit antibodies raised against L. major
histones H2A, H2Avariant, H2B, H3, and H4 (Wong and Beverley, in preparation). Were
pooled at a ratio of 3:2:3:3:1 by titer as determined by Western blot and used at a dilution
of 1:750 (Wong and Beverley, in preparation). BrdU was detected with a rat monoclonal
antibody (Abcam) used at 10 μg ml−1. For dual-labeling experiments involving YFP,
Alexafluor488-conjugated rabbit anti-GFP antisera (Invitrogen) was used at a
concentration of 8 μg ml−1. The amastigote-specific mouse monoclonal antisera T17 and
T18 were a gift from Charles Jaffe (Hebrew University) and were diluted 1:400 (14).
Paraflagellar rod (PFR) was detected with the mouse monoclonal antibody L8C4
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(provided by Keith Gull), and was used at a dilution of 1:50 (13). Lipophoshoglycan
(LPG) was detected using two different antisera. For most experiments, Gal-substituted
LPG was detected with the mouse monoclonal antibody WIC79.3 (23), which was used
at a 1:250 dilution. Where specified, “metacyclic LPG”, in which most of the galactose
side chains are capped with arabinose, was detected with the mouse monoclonal antibody
3F12 (23), used at a 1:100 dilution.
The following fluorescent secondary antibodies were used: Alexafluor488 goat antirabbit, Alexafluor555 goat anti-rabbit, Alexafluor633 goat anti-rabbit, Alexafluor488
goat anti-mouse, Alexafluor594 goat anti-mouse, and Alexafluor488 goat anti-rat
(Invitrogen, all used at a concentration of 2 μg ml−1).
Immunofluorescence staining and confocal microscopy
At the designated time points, samples were fixed in 4% (w/v) paraformaldehyde in
phosphate-buffered saline (PBS) for 10 minutes. Samples were washed in PBS, and then
blocked and permeabalized in PBS containing 5% (v/v) normal goat sera (Vector labs)
and 0.1% (v/v) Triton-X-100 for 30 min. The samples were then stained with various
combinations of primary antibodies (as described in the text) for 1 h. Unbound antibody
was then washed off in PBS and primary antibodies were detected with combinations of
fluorescent secondary antibodies (as described in the text) for 40 min, followed by a
second wash in PBS. In experiments involving BrdU, fixed samples were washed with
distilled water prior to a 40 minute incubation in 2 N HCl. Samples were then extensively
washed in PBS prior to blocking and permeabilization as described above. Samples were
incubated in anti-BrdU antisera for 2 hours. For experiments involving EdU, we labeled
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the EdU according to the manufacturer’s protocol (Life Technologies) prior to antibody
labeling.
Following staining, all samples were mounted in ProLong Gold (Invitrogen). All
microscopy was performed on a Zeiss 510 META confocal laser scanning microscope.
Cutoffs for saturation and background levels were adjusted with Photoshop software
(Adobe).
Quantitation of LPG abundance
Samples were stained to detect parasite histones and PGs and confocal microscopy
performed as described above. 3-dimensional confocal image stacks were then
compressed into a single 2-dimensional image which was then used for subsequent
analysis. For samples harvested less than 24 hours post infection, at which time the
parasite’s outline could be visualized with WIC79.3 staining, Volocity software
(Improvision) was used to trace the outline of the parasites and then measure the sum of
the WIC79.3 (red) intensity within the traced area. For samples harvested 24 hours or
later after infection, this method was unusable because the outline of the parasites was
increasingly invisible. Thus, we measured the sum of WIC79.3 intensities within a 44.8
µm2 circle centered at the parasite nucleus. We did not use this method with parasites at
time points prior to 24 hours because a circle is a poor approximation of the elongated
shape of metacyclic-stage parasites.
Statistics
Unless stated otherwise, the data reported throughout the paper is the mean of at least
three independent experiments in which >400 parasites were scored per experiment. Data
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are presented as the mean ± the standard deviation. P values were determined either by a
Student’s t-test or a Chi-square test.
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Results
Characterization of differentiation markers and their expression following L. major
infection of peritoneal macrophages
First we sought markers that clearly distinguished L. major metacyclic parasites from
authentic amastigotes, obtained after 120 hr infection of peritoneal macrophages in vitro,
or visualized in sections taken from mice infected for several weeks. While a number of
genes showing quantitative differences in promastigote or amastigote expression are
known from microarray or proteomic studies, few show qualitatively on/off properties
suitable for use in characterization of the tempo of amastigote differentiation on a cellular
level (24-29). We explored a number of candidates, and ultimately identified five suitable
for use. As shown in Fig. 1, these clearly distinguish between metacyclic-stage parasites
and parasites 72 hours after infection of peritoneal macrophages (PEMs), a time at which
many of the parasites in these cells are replicating amastigotes (below).
As a marker ‘on’ in promastigotes and ‘off’ in amastigotes, we chose the expression of
the paraflagellar rod protein PFR1, which accompanies the loss of the flagellum during
differentiation (Figure 1A) (30). As markers ‘off’ in promastigotes and ‘on’ in
amastigotes, we followed the expression of the amastigote-specific antigens recognized
by the monoclonal antibodies T17 and T18 (14). The epitopes recognized by the two
antisera clearly differed in their cellular localization within amastigotes, suggesting they
recognize different amastigote molecules. A third such marker consisted of a YFP
transgene inserted into the ribosomal SSU locus, where YFP is “off” in metacyclic
promastigotes but “on” in other stages (Figure 1D). While the mechanism controlling the
YFP transgene expression have not been definitively established, preliminary studies
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suggest that the reduction in YFP fluorescence and protein results from a decrease in YFP
mRNA abundance (data not shown). Lastly, we monitored parasite DNA synthesis
following metabolic labeling with BrdU or EdU (31, 32), to detect the transition between
non-replicating metacyclics and replicating amastigotes.
Sequence and timing of metacyclic/amastigote differentiation marker expression.
We compared the sequence and timing of amastigote marker induction in PEMs. These
results are summarized in Fig. 1E. The first marker change was the loss of reactivity with
anti-PFR1 antisera. By 4 hours after infection (the earliest time point attempted), most
parasites had lost anti-PFR staining (89 ± 6%), and by 24 hours essentially no parasites
(0.2 ± 0.6%) were recognized with this antibody. Interestingly, loss of PFR1-reactivity
did not completely coincide with the disappearance of long flagella, as staining with antiphosphoglycan antisera or mAb T17 (see below) revealed that some parasites retained
long flagella even at 24 hours post-infection (data not shown).
Next we observed that reactivity with mAbs T17 and T18 rapidly appeared. At four hours
after infection, a small percentage of parasites (<5%) were weakly reactive with either
MAb, but by 8 hours post-infection 37 ± 7% and 41 ± 12% were positive for T17 or T18
reactivity, respectively (Fig. 1E). By 11 hours after infection, >90% of the parasites
were recognized by these antisera, and at 24 hours post infection, 94 ± 4% of the
parasites are T17+ and 92 ± 8% are positive for T18 reactivity.
SSU:YFP transgene expression first became weakly detectable 8 hours after infection,
with 18 ± 3% of the parasites YFP+ at 12 hours post-infection. By 24 hours, the
percentage of YFP+ parasites had increased to 51 ± 13%. Interestingly, while the percent
of parasites displaying YFP fluorescence continued to increase reaching 70 ± 17% at 72
41

hours post-infection, it never became 100%. Similarly, only ~70% of parasites within
infected mouse footpads were YFP+ 2 weeks following infection, a time of vigorous
parasite replication and expansion. Currently we do not understand why 100% YFP
expression is not attained.
The last marker transition was the commencement of DNA replication. While all other
markers had achieved ‘full’ expression by 24 hr (PFR off, T17, T18, and SSU:YFP on),
only 8 ± 1% of the parasites showed labeling with anti-BrdU antisera at this time. The
percentage of BrdU-positive parasites increased such that at 72 hours post-infection, 72 ±
13% of the parasites were BrdU+. Together, these data show that the amastigote markers
are induced in an orderly sequence with promastigote-specific PFR1 gene expression
turning off by 4 hr post-infection, T17 and T18 expression turning on by 8-11 hr,
SSU:YFP expression turning on by 11-24 hr, and finally replication commencing around
24 hr (Fig 1F). While we did not seek to rigorously establish whether various markers
appeared homogeneously in sequence, the quantitative aspects suggest that this is likely.
This supposition was supported by limited preliminary tests examining co-expression
(not shown).
These data establish a useful developmental sequence of marker expression for analysis
of Leishmania differentiation. Whether these transitions are functionally connected or
interdependent, or occur independently of one another, has not been investigated.
Amastigote marker induction in bone marrow-derived macrophages and dendritic cells
We then examined the ‘differentiation sequence’ markers above in L. major metacyclic
infections in two other cell types, bone marrow-derived macrophages (BMM) or dendritic
cells (DCs). These data are plotted for each marker separately for the three cell types in
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Fig. 2, or by cell type in Fig. 3 (BMM) and Fig. 4 (DC). Overall, the relative order of
developmental marker expression was conserved amongst the three cell lines, albeit with
a few differences amongst specific markers and in the overall rate.
Loss of anti-PFR1 reactivity in BMM and DCs was similar to what is seen in PEMs at
either 4 or 24 hours post-infection (P > 0.17 by Student’s t-test; N = 3 experiments) with
35 ± 25% and 0.5 ± 0.6% of parasites in BMMs and 15 ± 13% and 0.4 ± 4% of parasites
in DCs labeling at these time points (Figure 2A). The induction of T18 reactivity and
SSU:YFP fluorescence also showed similar time courses in the three cell types (P > 0.16
for T18 and P > 0.2 for YFP by Student’s t-test; N = 3 experiments; Figs. 2B and 2C).
Induction of T17 reactivity appeared to be slower in BMMs than in PEMs in that a lower
percentage of the parasites at 8 hours post-infection were T17+ (10 ± 8%, P < 0.01 by
Student’s t-test; N = 3 experiments). This difference disappeared by 24 hours, with 89 ±
10% of the parasites within BMMs showing T17-positivity. With the T17 marker,
parasites within DCs were intermediate between the profile seen for PEMs and BMMs,
but were not significantly different from the PEM results (P > 0.08 by Student’s t-test; N
= 3 experiments; Figure 2D). Lastly, parasites within BMMs and DCs also did not initiate
DNA synthesis until after 24 h, as measured by BrdU-incorporation, as only 8 ± 2% of
parasites within DCs and 5 ± 4% of parasites within BMMs were positive at 24 h. At 72
hours post infection significantly fewer parasites within DCs (46 ± 9%; P = 0.02 by
Student’s t-test; N = 3 experiments) and BMMs (35 ± 15%; P = 0.01 by Student’s t-test;
N = 3 experiments) are BrdU+ than is seen in PEMs (72 ± 13%; Figure 2E).
When plotted by cell type, it is evident that the parasites show a similar progression in
developmental marker expression in all three cell types (Fig. 1E, 3, 4). For the most part
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the timing of marker expression was also conserved, other than reduced numbers of
parasites entering the cell cycle in BMM and DCs relative to PECs (Fig 2E).
Quantitation of LPG expression.
LPG expression was assessed at different time points after infection of PEMs by its
reactivity with the phosphoglycan (PG) specific monoclonal antibody WIC79.3, which
recognizes galactose modifications of LPG and proteophosphoglycan (PPG) (23). While
these modifications are often capped by arabinose in “metacyclic” LPG in L. major, we
have shown previously that >90% of metacyclic parasites enriched through the gradient
centrifugation protocol performed here retain some level of non-capped Gal-residues (20,
23), and thus are detected by this antibody. While PPGs also react with WIC79.3, they
are expressed at much lower levels than LPG (<1%) (19).
First LPG expression was assessed qualitatively, scoring parasites as either “LPGpositive” or “LPG-negative”. By this assay, 99 ± 1% of metacyclic stage parasites were
LPG+. By 24 hours after infection of PEMs, this number had declined to 81 ± 2%, and by
72 hours post infection, only a few (5 ± 3%) of the parasites had detectable LPG.
Preliminary experiments monitoring the presence of arabinose-capped metacyclicspecific LPG using the monoclonal antibody 3F12 (23), yielded comparable results with
a modest increase in the percentage of 3F12-negative parasites by 24 hours after infection
and almost complete loss of 3F12+ parasites by 72 hours post infection (Supplemental
figure S1).
The intensity of WIC79.3 reactivity was then used to quantitate LPG expression per cell
(Figure 5A). To establish the background we used the LPG-deficient lpg1- mutant
described previously (19). By this assay, all metacyclic parasites show LPG expression,
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with a mean labeling intensity of 45,900 ± 23,300 arbitrary units (see the Methods for the
procedure used for delineating parasite boundaries and the intensity of binding).
Interestingly, at 20 minutes post infection the mean per-cell WIC79.3-reactivity increases
to 66,100 ± 24,500 units. Thereafter, LPG expression gradually declined (albeit with
some heterogeneity) such that at 48 and 72 hours post infection, the parasites reach
background levels of WIC-reactivity (below 20,000 units). Consistent with the results
from the qualitative assay a few (5-10%) of the parasites at 48 and 72 hours post infection
retained detectable WIC79.3-reactivity, which in some cases was as high as seen in
metacyclics. Thus, LPG is no longer present at significant levels on most parasites by 48
hours post infection of PEMs.
High levels of LPG retained on parasites in BMMs and DCs
We then examined LPG expression following infection of L. major metacyclics of BMM
and DCs (Figs. 4B-D). At 24 hours post-infection, 19 ± 2% of parasites within PEMs
have lost LPG expression by the qualitative assay described above. In contrast, fewer
parasites in BMMs (8 ± 5%; P < 0.05 by Student’s t-test; N = 3 experiments) lost LPG
expression at this time point, with the parasites in DCs yielding a result intermediate
between the two types of macrophages (12 ± 6% LPG-negative). The most striking
difference was seen at 72 hr; while 95 ± 3% of parasites within PEMs are LPG- at 72
hours after infection, many parasites in both BMMs and DCs retained LPG expression at
this time point, with 65 ± 5% of parasites in BMMs (P < 10-4 by Student’s t-test; N = 3
experiments) and 37 ± 14% (P < 0.02) of parasites in DCs retaining high levels of LPG
(Fig. 5B and C).
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We then measured LPG expression per cell on all three types at 24 and 72 hr (Fig. 5D).
Consistent with the results from the qualitative assay described above, parasites within
BMMs and DCs retained LPG expression for a longer period of time. Whereas the mean
per-cell WIC79.3 intensity of parasites within PEMs 24 hours after infection was reduced
by ~30% relative to that of metacyclic stage parasites (P < 0.001 by Student’s t-test; N =
3 experiments), the mean LPG levels in parasites within BMMs and DCs had not
declined significantly, remaining above 41,300 units. By 72 hours, however, this value
did decline for parasites within DCs and BMMs, which had mean LPG expression of
24,900 ± 15,400 and 28,600 ± 19,200 units, respectively. At 72 hr however many
individual parasites within both BMMs and DCs showed little LPG expression, similar to
that of the lpg1- LPG negative parasites. Nevertheless, the mean WIC79.3 intensity of
parasites within PEMs at 72 hours after infection was 17,600 ± 8,400 units, significantly
less than that for parasites within either BMMs or DCs (P < 10-5 by Student’s t-test; N = 3
experiments). Importantly, even at 72 hours post-infection, many of the parasites that
were classified as “LPG+” showed LPG expression comparable to metacyclic-stage
parasites. This suggests that a population of parasites within BMMs and DCs retained
biologically relevant amounts of LPG for at least 72 hr in BMM and DCs, but not PECs.
LPG-retaining parasites within bone-marrow dendritic cells are non-dividing
We asked whether the sub-population of cells retaining high levels of LPG after 72 hr
following infection of BMM or DCs had initiated DNA synthesis or not. For these
experiments, we made use of the Click-iT EdU system (Life Technologies, to facilitate
simultaneous visualization of LPG and the incorporation of thymidine analogue (EdU)
into parasite DNA. DCs were infected with L. major metacyclics and then cultured in the
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presence of EdU for 72 hours, after which the samples were fixed and stained to
simultaneously detect L. major histones, LPG, and EdU. For these studies, the results
obtained for the percent of parasites that were labeled with EdU were in the ballpark of
the results described above with BrdU. We imaged a total of 1174 parasites, 38% of
which were EdU+ and 21% of which were LPG+ (Figure 4A). Assuming that there is no
relationship between a parasite’s LPG-positivity and DNA synthesis, as a null hypothesis
we would expect that 38% of the LPG+ parasites should be EdU+. Instead, while 46% of
LPG- parasites are EdU+, only 7% of the LPG+ parasites are EdU+, significantly less than
what would be expected (p < 10-30 by a Chi-square analysis, N = 2 experiments, 1174
parasites; Figure 4B).
Thus, the parasites within DCs retaining high levels of LPG expression have not yet
entered the cell cycle. This finding raises the question as to whether the loss of LPG and
the induction of DNA synthesis is an ordered process. To address this, we performed the
same experiment as above, only this time on PEMs 24 hours post-infection, a time point
at which most parasites retain LPG expression and in which some parasites have become
BrdU-positive (see Figure 1F). Unlike in DCs at 72 hours post infection, in PEMs at 24
hours post-infection a similar percentage of LPG+ and LPG- parasites are EdU+,
suggesting that LPG loss and DNA synthesis are not ordered in PEM infections (p = 0.41
by a Chi-square analysis; N = 2 experiments, 1255 parasites; Figure 4B).
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Discussion
Amastigote development in peritoneal macrophages
Although the primary aim of our study was to address parasite differentiation and LPG
loss within DCs, we first had to characterize the differentiation process within
macrophages, cells in which the parasites are known to differentiate. These studies were
carried out within starch-elicited peritoneal macrophages, which represent our goldstandard host cell type because they are permissive to all of the stages of parasitism
(entry, differentiation, and parasite replication). Some of the developmental changes
associated with amastigogenesis, such as the loss of PFR expression, happened very
rapidly upon parasite infection of these cells, with more than 90% of the parasites
displaying a PFR- phenotype by 4 hours post-infection. Other developmental changes as
assessed by amastigote markers occurred later, with T17 and T18 reactivity being the
next “markers” to be induced, followed by the induction of YFP fluorescence. The
findings that the induction of amastigote markers appears to occur in an ordered manner
is consistent with the ordered progression of gene expression changes seen by microarray
studies as L. donovani differentiates in axenic culture (27). These changes preceded reentry into the cell cycle, as they had largely gone to completion by 24 hours post
infection, a time point at which only 8% of the parasites were BrdU+.
All of the amastigote markers are induced on parasites within DCs
Having established the timing and sequence of amastigote marker induction within
PEMs, we then asked whether L. major metacyclic-stage parasites behave similarly
within DCs, one of the host cell types with which parasites interact first upon infection in
vivo and which may be important either as hosts for or killers of parasites and have
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important roles in the establishment of either protective or pathological immune
responses (2, 33-35). As a control for these studies, we also assessed the differentiation of
the parasites within bone marrow-derived macrophages (BMMs) in order to better
understand the range of parasite differentiation phenotypes in different types of
macrophages. Parasites within BMMs and DCs clearly did not remain metacyclics, as
they became PFR-, T17+, T18+, and YFP+ in a manner similar to that of parasites within
PEMs. In addition, by 24 hours after infection, a comparable percentage of the parasites
within BMMs and DCs were BrdU+. Thus, at this time point each amastigote marker is
present on at least a few parasites, consistent with at least partial if not complete
differentiation within DCs.
Fewer parasites in BMMs and DCs undergo DNA synthesis or lose LPG expression
Although all amastigote markers were present on parasites within DCs and BMMs,
significantly fewer of the parasites within these cells became BrdU+ or LPG- by 72 hours
post-infection than what is seen in PEMs. Importantly, these LPG+ parasites likely have
biologically relevant levels of LPG, as quantitation demonstrated that they express
comparable amounts of LPG to metacyclic-stage parasites on a per-cell basis. Duallabeling experiments showed that the LPG+ parasites in DCs at this time point tended to
be preferentially BrdU-, suggesting that the parasites with residual LPG were not
replicating. Nevertheless, we argue that the LPG+ parasites are viable for several reasons.
First, while killed intracellular Leishmania are degraded very quickly by host cells (36),
the LPG staining of the parasite’s surface revealed that the LPG+ parasites appeared
intact and morphologically normal. In addition, in BMMs where 65% of the parasites are
LPG+, we saw that 66% of total parasites showed bright YFP fluorescence, implying that
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at least some of the LPG+ parasites were positive for endogenous YFP fluorescence. Such
fluorescence would be lost in killed parasites arguing that LPG+ parasites are alive (37).
Taken together, these results demonstrate that in bone marrow-derived DCs and
macrophages, a population of parasites exist up to 72 hours after infection which have a
phenotype that is intermediate between metacyclics and amastigotes. Similar to
amastigotes, they are PFR-, T17+, T18+, with some being YFP+. However, they express
levels of LPG similar to what is seen on metacyclic stage parasites and have not resumed
replication. Such intermediate phenotypes could arise either because amastigogenesis is a
slower process within BM-derived cells or alternatively the parasites could instead be
arrested in some intermediate stage in development. Further studies will be required to
distinguish between these two models. Regardless, either process results in the existence
of parasites which retain the expression of LPG and potentially other ‘early’ virulence
factors. The retention of these virulence factors may have important effects on the
infected hosts. LPG has demonstrated roles in parasite survival in macrophages and
neutrophils, protection against complement-mediated lysis, oxidant avoidance, and the
inhibition of phagolysosomal fusion (7, 8, 12). LPG retention by the parasites may serve
to prolong the effects of this virulence factor as the parasites transit through cell types of
‘first contact’.
What type of parasite could be transferred from DCs to macrophages?
Invading metacyclic-stage parasites are thought to interact predominantly with cell types
other than macrophages in vivo, yet by 48 hours after infection most parasites are found
within macrophages (38). If we assume that all parasites enter macrophages by way of
DCs, then the parasite phenotype encountered by macrophages would be entirely
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dependent on the parasite phenotype(s) present at the time of transfer. We evaluated the
phenotype of parasites within DCs at 24 and 72 hours post-infection, time points bookending the time during which parasite transfer from DCs to macrophages likely takes
place. At 24 hours post infection, almost all parasites are positive for the amastigote
markers PFR, T17, and T18, yet retain LPG and cell cycle arrest. By 72 hours after
infection roughly a third of the parasites retain LPG, cell cycle arrest, and potentially
other ‘metacyclic’ characteristics. Thus, should parasite transfer occur at any time
between 24 and 72 hours post infection, macrophages would be expected to encounter a
mix of parasite phenotypes including both LPG- and LPG+ parasites, with the LPG
potentially exerting effects not just on the DC but also on the macrophage upon
subsequent transfer.
In reality, DCs are not the only cell type with which metacyclic-stage L. major interact,
and the parasites are thus transferred to macrophages from these other cell types as well.
In order to understand the parasite phenotype(s) that may be transferred from these cells
to macrophages, the ability of the parasites to differentiate within these cells must be
determined. Although it may be tempting to assume that the timing of parasite
differentiation within different host cells may be similar to what is seen by one of the
three cell types assessed here, our data suggest that amastigogenesis is strongly
dependent on conditions, and such assumptions may not be correct. Some of the most
profound differences seen between cell types in terms of parasite differentiation were
between different sources of macrophages (PEMs versus BMMs). These two types of
macrophages could differ in several ways that are potentially relevant to the parasite,
including in their lysosomal pH or contents or the fusogenicity of Leishmania-containing
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endosomes, with such differences being either positive or negative regulators of
amastigogenesis. Thus, the ability of L. major to undergo amastigogenesis within other
host cell types must be addressed experimentally. In fact, our results in DCs appear to
contrast with what is seen in human peripheral blood-derived neutrophils, in which at
least some L. major parasites retain the long, highly motile flagella that is characteristic
of promastigotes up to 42 hours post-infection (39).
Potential uses of amastigote markers
In order to address the ability of L. major to differentiate within DCs, we first had
to develop amastigote markers, as such tools are limited with Leishmania in general and
L. major in particular. As the induction of some of the markers (PFR loss and induction
of T17 and T18 antigens) appear to be ordered, these markers can be used to determine
the extent to which a parasite has undergone differentiation, with a parasite that is
positive for all markers being considered fully differentiated. These markers potentially
have numerous applications in addition to those for which they were used here. Such uses
might include the evaluation of putative L. major axenic amastigote lines, with the goal
of finding conditions in which parasites are “positive” for all amastigote markers. In
addition, these markers could be used to identify environmental signals that positively or
negatively affect amastigogenesis in vitro, as a higher percentage of parasites would be
expected to be positive for the amastigote markers as differentiation conditions improve.
Ultimately, the identification of amastigote markers lays the groundwork for genetic
studies of amastigogenesis so as to better understand parasite developmental biology.
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Figure legends
Figure 1. Characterization of amastigote markers in peritoneal macrophages (PEMs). (AD) Comparison of marker expression between metacyclic parasites (left) or parasites 72
hours post infection of PEMs (i.e. amastigotes, right). (A) Parasite nuclei are detected
with antisera against L. major histone proteins (green), and PFR is shown in red. (B)
Parasite histones, red. mAB T17, green. (C) Parasite histones, red. mAB T18, green. (D)
Endogenous YFP fluorescence (yellow) overlaid onto DIC image. Scale bar represents 5
µm. (E) Timing of marker induction. The percentage of parasites showing an
“amastigote-like” phenotype for the various markers is plotted as a function of time after
infection. N = 3 experiments, error bars represent standard deviation. (F) Summary of the
data in (E) showing the relative timing of amastigote marker induction in PEMs.
Figure 2. Parasites within bone marrow-derived macrophages (BMMs) and dendritic
cells (DCs) induce PFR, T17, T18, and YFP markers similarly to in PEMs. For all
graphs, PEM data is represented with black diamonds, BMM data is represented with
grey squares, and DC data is represented with open triangles. The data shown is the
average of three experiments, and error bars represent the standard deviation. (A) PFR
loss. (B) Induction of T18 reactivity. (C) Induction of YFP fluorescence. (D) Induction of
T18 reactivity. Data shown is the mean of three independent experiments, error bars
represent standard deviation. (E) BrdU-incorporation by parasites in PEMs, BMMs, and
DCs. Infected host cells were cultured in media containing BrdU for 24 or 72 hours after
infection. Black bars, PEMs. Grey bars, BMMs. White bars, DCs. ** denotes P < 0.05
by Student’s t-test.
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Figure 3. The percentage of parasites within BMM showing an “amastigote-like”
phenotype for the various markers is plotted as a function of time after infection. N = 3
experiments, error bars show standard deviation.
Figure 4. The percentage of parasites within DCs showing an “amastigote-like”
phenotype for the various markers is plotted as a function of time after infection. N = 3
experiments, error bars show standard deviation.
Figure 5. Loss of LPG expression following infection of PEMs, BMMs, and DCs. (A)
Anti-LPG fluorescence intensity on a per-parasite basis. Anti-LPG intensity of WT
metacyclic-stage parasites as well as at various time points after infection of PEMs was
measured as described in Methods. As a negative control, the anti-LPG intensity of L.
major lpg1- (open circles) was measured 0.3 hr after infection of PEMs. The grey line
shows the mean anti-LPG intensity of “LPG-negative” WT parasites as determined by the
qualitative assay plus two standard deviations, and any parasite with anti-LPG values
below that line would be considered LPG-negative. Data shown is pooled from at least
two independent experiments. Black bars represent geometric mean of the data for each
sample. (B) Representative images comparing the LPG-positivity of purified metacyclics
and parasites within PEMs, DCs, and BMMs at 72 hours post-infection. Parasite nuclei
are shown in green, LPG is shown in red. Scale bar represents 5 µm. (C) Percent of
parasites within the three host cell types that are LPG+ as determined by the qualitative
assay. PEM data is represented with black diamonds, BMM data is represented with grey
squares, and DC data is represented with open triangles. N = 3 experiments, error bars
show standard deviation. (D) Quantitation of LPG on the surface of parasites within
PEMs, BMMs, and DCs at 24 and 72 hours post infection. For comparison, anti-LPG
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intensity data for metacyclic-stage parasites is also shown (open circles). The grey line
shows the cut-off for LPG-positivity. Data shown is pooled from three independent
experiments. Black bars represent geometric mean of the data for each sample, and P
values were calculated by a Student’s t-test.
Figure 6. LPG-retaining parasites within DCs 72 hours post-infection have not undergone
DNA synthesis. Parasites were cultured in the presence of thymadine analogue (EdU) for
72 hours following infection of DCs or PEMs. Cells were stained to detect EdUincorporation (green), LPG (red) and parasite nuclei (blue). (A) Representative image of
parasites within DCs stained as above. Scale bar represents 5 µm. (B) Percent of parasites
within DCs 72 hours post-infection (white bars) or PEMs 24 hours post-infection (grey
bars) that are positive for EdU-incorporation. Data shown include the percent of total
parasites that are EdU+, as well as the EdU-positivity of parasites that are either LPGnegative or LPG-positive. In DCs at 72 hours post-infection, almost all EdU+ parasites
are LPG-negative. This is not the case in PEMs 24 hours post-infection, in which a
similar percentage of parasites within the LPG+ and LPG-negative pools are EdU+. N = 2
experiments. * denotes statistical significance as determined by a χ2 test described in the
text.
Supplemental figure S1. Loss of arabinose-capped “metacyclic” LPG by parasites within
PEMs. PEMs were infected with L. major and harvested 2, 24, and 72 hours after
infection. (Top) Ara-capped LPG is detected with mAB 3F12 (green), and parasite
histones are shown in red. Scale bar represents 5 µm. (Bottom) Percent of parasites that
were 3F12+ at indicated time points.
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Chapter 3

Replicating and quiescent sub-populations of persistent L. major suggest a “stem
immunogen” model of concomitant immunity
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Abstract
Following Leishmania major infection, small numbers of parasites persist indefinitely in
the host in the absence of pathology. Persistent parasites play important roles in
concomitant immunity and act as reservoirs for transmission and/or reactivation. We
sought to examine the replication and localization of persistent L. major in mice. We used
an in vivo BrdU-labeling assay to show that persistent parasites replicate, albeit ~50% as
much as acute-phase parasites resulting from the existence of a poorly-replicating subpopulation of parasites unique to persistent infections. Persistent parasite replication
occurs within macrophages and dendritic cells, ~80% of which synthesized high levels of
iNOS protein, an enzyme implicated in parasite killing. However, the parasites within
iNOS+ cells appeared morphologically normal and showed comparable BrdU labeling to
parasites within iNOS- cells suggesting at least transient survival within iNOS+ cells.
Since parasitemia remains roughly constant over time, persistent parasite replication
implies that parasites must also be destroyed. These data shed new light on the persistent
parasite paradigm, invoking a ‘stem immunogen’ model for concomitant immunity in
which a generally quiescent reservoir periodically undergoes replication, thus
maintaining itself while targeting many progeny parasites for destruction within
professional antigen presenting cells and consequent maintenance of immunity.
Attenuated lpg2- L. major, a proposed model of WT persistence capable of vaccinating
susceptible BALB/c mice against virulent challenge, closely resembled persistent WT in
most respects (e.g. replication and localization within iNOS-expressing phagocytes), but
differed in its association with host arginase I expression in C57BL/6, but not BALB/c,
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mice. As lpg2- fails to vaccinate C57BL/6 mice, elevated arginase I expression may be a
negative correlate of anti-Leishmania immunity.
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Introduction
As long-term infection of a host can increase a pathogen’s chances of transmission, an
array of viral, bacterial, and eukaryotic pathogens have evolved the ability to prolong
their relationship with their hosts. A subset of pathogens, including Mycobacterium
tuberculosis, Toxoplasma gondii, and Leishmania major remain indefinitely within their
hosts in small numbers without causing obvious illness: a condition which we refer to as
a “persistent” infection. Despite the absence of overt pathology, such persistent infections
are of great medical importance as they serve as reservoirs for transmission, reactivate to
cause disease (1), or protect against subsequent infections either by their own species or
by different pathogens (2), a process known as concomitant immunity.
Persistence is a significant but under-studied aspect of the biology of parasites of the
genus Leishmania, which are the causative agents of leishmaniasis. These parasites are
transmitted as metacyclic-stage promastigotes to humans by the bite of an infected sand
fly. They are then engulfed by phagocytes such as macrophages, where they differentiate
into the amastigote stage and begin to replicate. In the case of Leishmania major, this
may produce an ulcerating skin lesion. In most human cases, as well as in experimental
infections of “resistant” mouse strains, the infection is eventually controlled by a Th1
type immune response, an important component of which is the induction of iNOS. It is
generally thought that iNOS-derived nitric oxide (NO) is responsible for killing
intracellular L. major, since iNOS knock-out mice fail to control infection (3, 4).
Following the development of this protective response, the number of parasites in
infected tissue declines dramatically, the lesion heals, and the host becomes immune to
subsequent L. major infection. However, a small, roughly constant population of viable
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parasites remains at the site of infection and in the lymph node draining that site for the
rest of the host’s life (5).
These persistent parasites are important for several reasons. First, despite their limited
numbers (~1000), persistent parasites can still be transmitted to sand fly vectors, and as
such, are a reservoir for the pathogen (6, 7). Second, they pose a substantial risk to
infected people in the event of immunosuppression, as the persistent parasites can
“reactivate” leading to severe disease (8). Finally, they may be beneficial to hosts with
intact immune systems, as they help maintain protective immunity against subsequent
Leishmania infections (9). Indeed, healed Leishmania infections are the gold-standard in
anti-Leishmania immunity, and to date no other vaccination approaches have been
successful in humans (10). Importantly, treatment of persistently infected mice to achieve
a sterile cure renders those mice susceptible to new infections (11), suggesting that the
persistent parasites are actively contributing in some way towards their host’s antiLeishmania immunity.
Because of the strong protective immunity conferred by persistent parasites, an attenuated
parasite line that could persist indefinitely without causing pathology would be a
promising candidate for development into a vaccine against leishmaniasis (12). Several
mutant lines of L. major, (including parasites lacking fructose-1,6-bisphosphatase or the
nucleotide sugar transporter LPG2) have these properties (13). Of these, lpg2- (which
lacks a GDP-mannose transporter required for the synthesis of parasite virulence factors
such as phosphoglycans), can vaccinate susceptible mice against virulent challenge (14).
In fact, because the number of viable lpg2- in an infected mouse is comparable to that of
WT persistent parasites, lpg2- has been proposed as a model for L. major persistence.
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One advantage of this model would be that it would allow the generation of a persistent
infection only a few weeks after infection with lpg2-, as opposed to months following
infection with WT (12).
Considerable evidence suggests that the host’s immune response is important to
simultaneously prevent reactivation and clearance of persistent parasites. For instance,
treatment of persistently infected mice with immunosuppressive drugs, iNOS inhibitors,
or the blockade of interferon-γ signaling rapidly results in increased parasite numbers and
the reappearance of disease symptoms (4). In contrast, depletion of CD4+CD25+
regulatory T cells or the blockade of IL-10 signaling both result in sterile cure in mice
(11, 15). It remains unknown, however, how persistent parasites modulate the host’s
immunostimulatory and immunosuppressive responses, or what role persistent parasites
(or attenuated lines such as lpg2-) have in maintaining protective immunity. In addition to
immunological studies, studies of persistent parasites themselves are crucial to help us
address these questions.
As the number of persistent parasites is roughly constant, we sought to determine if the
parasites at this stage of the infection replicate or if they are quiescent. To this end, we
developed a BrdU-incorporation assay and used it to show that acute-phase levels of
replication was taking place by a sub-population of parasites, while another subpopulation replicated poorly if at all. Taken together, persistent parasites replicate about
half as much as acute-phase parasites, in which a poorly-replicating sub-population is not
detected. We found that parasite replication takes place within macrophages and dendritic
cells in both sites of persistence (the footpad infection inoculation site and the draining
lymph node). Other cell types, including ER-TR7+ reticular fibroblasts, harbored 10% or
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less of persistent parasites. Constant parasite numbers despite constant replication implies
that parasite killing is also taking place. We hypothesized that iNOS-expressing cells
were the sites of parasite killing and found that ~70% of persistent parasites were within
such cells. Although the parasites observed within these cells appeared to be healthy and
replicating, we presume that at least some of the parasites within these cells are killed.
Continual parasite destruction and repopulation suggest a model by which persistent L.
major maintain protective immunity, namely by continual presentation of antigens from
killed parasites. This paradigm of constant immune stimulation could also explain the
concomitant immunity generated by other pathogens including herpesviruses and
Toxoplasma. We also assessed the replication and localization of lpg2- parasites. For
most parameters tested, WT persistent parasites and lpg2- were indistinguishable, further
supporting the use of lpg2- as a model of WT persistence. However, we found small
differences in the phenotype of the host cells infected by lpg2- and persistent WT, one of
which (an increased association within host arginase 1 expression) negatively correlates
with the ability of lpg2- to vaccinate different strains of mice.
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Materials and Methods
Parasite strains and culture
For most experiments, L. major strains LV39c5 (Rho/SU/59/P), Friedlin V1
(MHOM/IL/80/Friedlin), and lpg2- L. major (Δlpg2::HYG/ Δlpg2::HYG) (12) were
grown at 26OC in M199 M199 medium (US Biologicals) supplemented with 40 mM 4(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES) pH 7.4, 50 μM adenosine,
1 μg ml−1 biotin, 5 μg ml−1 hemin, 2 μg ml−1 biopterin and 10% (v/v) heat-inactivated
fetal calf serum (16). “Slow-growing” promastigote cultures were grown in RPMI 1640 +
L-glutamine (Invitrogen) supplemented with 37 mM HEPES pH 7.4, 47 μM adenosine,
.93 μg ml−1 biotin, 4.7 μg ml−1 hemin, 1.9 μg ml−1 biopterin and 0.9% (v/v) heatinactivated fetal calf serum(17). The WT LV39c5 parasites used here expressed GFP
from the ribosomal locus (SSU::IR1SAT-GFP) and were generated by transfecting SwaIcut plasmid B3538 into WT LV39c5 as described (16) and selecting for resistance to 100
µM nourseothricin and bright green fluorescence. The clone used in this study exhibited
virulence similar to WT in BALB/c mice (data not shown). Parasites deficient in the
arginase gene arg- (Δarg::HYG/Δarg::PAC) (18) were cultured in the above media
supplemented with 50 mM putrescine. Infective metacyclic-stage parasites were
recovered using the density gradient centrifugation method (19). Propidium iodide
staining of promastigotes was performed as described (20).
Mouse infections
Female C57Bl/6J mice (6-10 weeks old; Jackson Labs) were injected subcutaneously in
the left hind footpad with either 105 metacyclic WT or 106 metacyclic lpg2- parasites.
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Following infection with WT parasites, the mice developed lesions that resolved, as
determined by the absence of footpad swelling relative to the uninfected foot, ~4 months
after infection. For the purposes of this study, “persistent” infections were defined as any
time >1 month following the resolution of footpad swelling. Most studies with lpg2- were
performed between 1-2 months following infection. Where indicated, some studies with
lpg2- were performed 5 months after infection. Because lpg2- parasites can revert to
amastigote virulence (21), it was important to eliminate possible revertants from our
analysis. To do this, we did not include data from lpg2- -infected mice in which we found
> 150 parasites in a single section. We chose this cutoff because we calculate that such a
mouse would likely have ~10000 parasites in the footpad (based on the fact that a normal
footpad can yield ~60 sections and our observation that the number of parasites within a
section remains roughly constant within one mouse.)
Antibodies used
L. major nuclei were detected with a pool of rabbit antibodies raised against L. major
histones H2A, H2Avariant, H2B, H3, and H4 (pooled at a ratio of 3:2:3:3:1 by titer) (Wong
and Beverley, in preparation). For some experiments, this pool was used at a dilution of
1:750. For others, this pool of antibodies was directly conjugated to Alexafluor488
monoclonal antibody labeling kit according to the manufacture’s protocol (Invitrogen)
and the directly conjugated antibody used at a final concentration of 0.15 mg ml−1. GFP
was detected with a chicken anti-GFP antibody (AbCam) at a final concentration of 0.02
mg ml−1. F4/80 was detected with a rat monoclonal antibody (clone A3-1, AbD Serotec)
diluted to 1:250. CD11c was detected with a hamster monoclonal antibody (clone N418,
eBioscience) diluted to 1:250. ER-TR7 was detected with a rat monoclonal antibody
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(BMA Biomedicals) used at a final concentration of 0.01 mg ml−1. iNOS was detected
with a rabbit anti-iNOS (BD Transduction Labs) used at 1 μg ml−1. Relmα was detected
with a rabbit polyclonal antibody (Abcam) used at 0.8 μg ml−1. BrdU was detected with a
rat monoclonal antibody (Abcam) used at 10 μg ml−1. Goat anti-Arg1 (Santa Cruz) and
goat anti-Arg2 (Santa Cruz) were used at 2 μg ml−1. Rat anti-LY-6C mAb (clone RB68C5; kindly provided by L. D. Sibley) was used at a 1:250 dilution. Rabbit antiLeishmania arginase (kindly provided by B. Ullman) was used at a 1:1000 dilution. The
following antisera were screened for reactivity to nitrotyrosine in interferon-γ/LPS
stimulated macrophages: rabbit anti-nitrotyrosine (Santa Cruz Biotechnology, sc-55256;
Millipore, #06-284; Abcam, ab50185), mouse anti-nitrotyrosine (Santa Cruz
Biotechnology, sc-32757), and rat anti-nitrotyrosine (Abcam, ab6479))
The following fluorescent secondary antibodies were used: Alexafluor555 goat antirabbit, Alexafluor633 goat anti-rabbit, Alexafluor488 goat anti-rat, Alexafluor555 goat
anti-rat, Alexafluor633 goat anti-rat, Alexafluor568 goat anti-hamster, Alexafluor488
goat anti-chicken, Alexaflour555 donkey anti-goat, and Alexafluor647 donkey anti-rabbit
(Invitrogen, all used at 2 μg ml−1 concentrations).
Tissue preparation and histological staining
After euthanasia, infected draining popliteal lymph nodes or feet were harvested. The
infected tissue was then fixed for 1 h at room temperature in 4% (w/v) paraformaldehyde
in phosphate-buffered saline (PBS). After fixation, tissues were incubated at 4OC for in
10%, 20%, and then 30% (w/v) sucrose in PBS. After an overnight incubation in 30%
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sucrose, the tissues were embedded in O.C.T. compound (Ted Pella, Inc.), cut into 6 µm
thick sections using a cryostat, and mounted onto microscope slides.
Unless otherwise indicated, tissue sections were stained as follows. Slides were washed
in PBS, and tissue were then blocked and permeabolized in PBS containing 5% (v/v)
normal goat sera (Vector labs) and 0.1% (v/v) Triton-X-100 for 30 min. The sections
were then stained with various combinations of primary antibodies (as described in the
text) for 1 h. Unbound antibody was then washed off in PBS and primary antibodies were
detected with combinations of fluorescent secondary antibodies (as described in the text)
for 40 min, followed by a second wash in PBS. For some experiments, we needed to
simultaneously stain tissue sections with different antibodies that were both generated in
rabbits. To do this, the tissue was stained with an unlabeled rabbit primary antibody and a
fluorescently-labeled secondary antibody as described above. Next, the tissue was
blocked for 30 min with a buffer containing 5% (v/v) normal rabbit sera (Sigma Aldrich),
and then the second fluorescently conjugated primary antibody was used.
For TUNEL staining of the tissue sections, after all primary and secondary antibody
staining was finished, the sections were stained with the In Situ Cell Death Detection Kit,
TMR Red (Roche), according to the manufacturer’s protocol. All sections were mounted
in ProLong Gold reagent (Invitrogen).
BrdU staining and in vitro experiments
For all BrdU experiments, paraformaldehyde-fixed samples were permeabilized with
0.1% (v/v) Triton-X-100 in PBS for 15 min, washed in distilled water, and then
immersed in 2 M HCl for 40 min to denature the DNA. After extensive washing with
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PBS, the samples were incubated in a blocking buffer containing PBS and 5% (v/v)
normal goat sera and 0.1% (v/v) Triton-X-100, and were then stained as described in the
text in the methods above. All BrdU stains used a 2 h incubation with the anti-BrdU
antibody.
To test BrdU in promastigotes in culture, either log- or stationary-phase L. major
promastigotes were cultured in M199 media that contained 0.1 mM BrdU (Sigma) for the
indicated time, after which they were fixed in 4% (w/v) paraformaldehyde in PBS for 10
min and stained as described above. To test BrdU in infected macrophages in vitro,
starch-elicited peritoneal macrophages (PEMs) were harvested and infected as described
with stationary-phase parasites (22). Two hours after parasites were added, the
macrophages were washed to remove extracellular parasites and placed in media
containing 0.1 mM BrdU. The infected macrophages were maintained in BrdUcontaining media for the remainder of the five-day experiment. At two hours, 1 day, 2
days, and 5 days post-infection, samples were fixed and stained as described above.
BrdU incorporation assay in vivo
Several different methods were attempted to administer BrdU to the infected mice. In the
preferred method, infected mice were injected every 3 h hours for 18 h with 200 µl of
PBS containing 4 mg ml-1 BrdU into the peritoneal cavity and 50 µl of this solution
directly into the infected footpad, yielding a total dose of 6 mg BrdU. We also tried
administering BrdU in the drinking water (1 mg ml-1), via infusion using osmotic pumps
(Alzet #2001D, 7.2 mg total dose), and single intraperitoneal injections of 200 µl of PBS
containing 4 mg ml-1 BrdU. 24 h after the first dose, the mice were euthanized and
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footpad tissue prepared and stained as described above. Volocity image analysis software
(Improvision) was used to assist counting.
Generation of alternatively activated macrophages
PEMs were harvested and plated on glass coverslips. 24 h after isolation, the media was
replaced with fresh media containing 100 U ml-1 each of recombinant IL-4 (BD
Pharmingen) and IL-13 (BD Pharmingen) for 48 hours.
Comparison of iNOS staining intensity
PEMs were isolated and allowed to attach to glass coverslips. 24 h after isolation, the
media was replaced with fresh media containing 100 U ml-1 recombinant interferon-γ
(Chemicon) and 100 ng ml-1 LPS (Sigma). 24 h later, the cells were fixed in 4% (v/v)
paraformaldehyde and stained in parallel with footpad tissue sections from lpg2- infected mice with antibodies against L. major histones and iNOS, and nuclei were
stained with TOPRO-3 (Invitrogen). To determine the fluorescence intensity of iNOS per
cross-sectional area, the outline of each cell from a confocal stack was traced in Volocity
software (Improvision) and the sum intensity of all “red” pixels (iNOS) in the selected
area was divided by the total number of pixels in that area, yielding a mean pixel
intensity for the cross section.
Comparison of arginase staining intensity between persistent parasites and
promastigotes
Footpad tissue sections infected with persistent WT or log-phase WT promastigotes were
labeled to detect parasite arginase with a rabbit anti-Leishmania arginase antibody (a gift
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from B. Ullman, diluted to 1:1000) and parasite histones (with the fluorescentlyconjugated anti-histone antibody). Confocal images were acquired using identical
settings, and then Volocity image analysis software was used to determine the total
arginase fluorescence intensity on a per-cell basis. To do this, confocal stacks were
compressed into a single plane, and then the total arginase fluorescence intensity was
determined within a 2.28 µm radius circle centered on parasite nuclei.
Macrophage infections
PEMs were harvested and plated on glass coverslips in 24 well dishes. The following
day, some cells were stimulated with 100 U ml-1 recombinant interferon-γ (Chemicon)
and 100 ng ml-1 LPS (Sigma) with or without the iNOS-inhibitor L-NIL (Cayman
Chemical) at a concentration of 10 µM. Four hours later, metacyclic stage WT L. major
strain Friedlin V1 (MHOM/IL/80/Friedlin) that had been opsonized in C5-deficient
mouse sera were added to the wells with a parasite to PEM ratio of ~10:1. Two hours
later, extracellular parasites were removed by extensive washing, and some coverslips
were removed and stained with the DNA stain Hoechst to determine initial parasite titers.
24 hours after infection, nitrite production was determined by the Greiss assay (Sigma)
and samples were removed to determine parasite titers. The remaining samples were left
alone until 72 hours after infection, at which time some samples were removed to
determine parasite titers. Media containing various combinations of interferon-γ + LPS
and L-NIL was added at this time point. At 96 hours after infection, nitrite production
was determined by the Greiss assay, and all samples were stained to detect parasite nuclei
and DNA. For these experiments, ‘percent survival’ is defined as the ratio of the number
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of parasites per 100 PEMs at either 24 or 94 hours after infection with the number of
parasites per 100 PEMs 24 hours earlier.
Microscopy
All microscopy of was performed on a Zeiss 510 META confocal laser scanning
microscope. Cutoffs for saturation and background levels were adjusted with Photoshop
software (Adobe).
Statistics
Throughout the manuscript, data are presented as the geometric mean ± the standard
deviation. P values are calculated by the Student’s t-test method.
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Results
Development of a BrdU incorporation assay for Leishmania
Preliminary studies of the L. major cell cycle suggest that the parasites extend the
duration of G1 phase, but not S- or G2 phase, under conditions of slow growth in vitro
(Supplementary figure S1). This suggests that a BrdU-incorporation assay (23) would
allow us to determine if persistent parasites replicate in their hosts and, if so, to compare
the doubling time of persistent parasites with that of acute-phase parasites. To develop
this assay, we first examined parasites growing in logarithmic phase in vitro, labeled with
0.1 mM BrdU for various periods followed by fixation and staining with a pool of
antibodies specific to L. major histone proteins to label parasite nuclei and anti-BrdU
antisera (24). As expected, BrdU was incorporated into both the kinetoplast
(mitochondrial) DNA network and the nucleus. Under conditions where parasites
replicated with a doubling time of approximately 8 hr, the percent of BrdU+ cells rose
from 0 to 90% over a period of 9 hr (Figure 1A). Other studies employing longer labeling
times failed to increase the percentage to higher values, suggesting that this is the
technical limit of this experimental protocol. As expected, increasing parasite doubling
time results in a lower fraction of BrdU+ parasites (Supplementary figure S1) and
addition of BrdU for 12 hr to cultures that had been in stationary phase for 24 hours
yielded no BrdU+ cells (data not shown). Importantly, culture of L. major-infected
macrophages in vitro in the presence of BrdU for 72 hr resulted in up to 90% BrdUlabeling of intracellularly replicating amastigotes, indicating that BrdU can enter the
phagolysosome.
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We next tested the ability of BrdU to label replicating parasites in acute mouse infections
(2-3 weeks post-infection). We tried several different methods to deliver BrdU to the
mice including in the drinking water, by intraperitoneal injection, through subcutaneous
infusion from surgically implanted osmotic pumps, and via injection of BrdU into the
peritoneum combined with direct injection of BrdU into the infected footpad. Mice were
sacrificed 24 hr after the beginning of the dosing period and the strategy that yielded the
highest percentage of BrdU+ parasite nuclei was determined.
Although all of the above strategies resulted in BrdU+ host cell nuclei within our acutelyinfected tissue sections, BrdU+ parasites were only detected in mice that received the
combined intraperitoneal and subcutaneous footpad BrdU injections. We found that the
percentage of parasites that labeled in a 24 h period increased linearly with the number of
doses (Figure 1B). We adopted a dosing regimen of 6 doses given every 3 h as a
‘standard’ protocol as it presented the maximum dosing schedule tolerable to both the
mouse and experimenter. Assuming a 24 hr labeling period and a parasite doubling time
of 60 h (as determined by the use of luciferase-expressing parasites; Hickerson et al,
unpublished data), we calculate that 40% of acute-phase parasites should be BrdU+.
Using the above protocol, 44 ± 6% of acute-phase L. major were BrdU+ 24 h after the
first dose of BrdU, a value which is consistent with our calculations and which we use as
representative of “maximal” replication. Throughout the remainder of this manuscript, we
will use the following nomenclature to summarize our summary statistics: N = # of
experiments (E) / total # of mice (M) / total # of parasites (P). Thus, for the experiment
described above, N = 2E / 5M / 5289P.
Persistent parasites replicate in vivo
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We then tested whether persistent L. major incorporate BrdU into their DNA. Here, we
define the asymptotic “persistent” phase as >1 month following the resolution of footpad
swelling at the inoculation site. When persistently infected mice were treated with BrdU
as described above, 19 ± 6% of persistent parasites had BrdU+ nuclei (N = 2E / 6M /
578P; Figure 1C and D). These data establish for the first time that persistent parasites
replicate in vivo.
As a second sign of parasite replication, we developed an indirect assay based on the
distribution of parasites within the tissue. This assay is based on the assumption that in
the persistently-infected state, host cells are initially infected by a single parasite, as the
low number of parasites present in the tissue makes multiple independent infections of
the same host cell unlikely. Thus, host cells containing two or more parasites can be
viewed as sites of intracellular replication. Using this indirect assay, we regularly found
instances in which host cells contained between 2-20 L. major cells, which we refer to as
“parasite clusters”. Roughly half of all infected cells contain 2 or more parasites, and
~80% of all parasites are found in “clusters” (N = 3E/8M/888P; 386 infected cells; Figure
2A and B).
Interestingly, the percentage of BrdU+ parasites was about 50% as much as that of acutephase parasites (P < 0.0001 by Student’s t-test). Assuming that persistent parasites
replicate as a homogeneous population, the percent labeling observed here suggests about
2-fold slower replication, or a doubling time of ~120 hr. Alternatively, these data would
fit a model where about ½ of the parasites replicate at rates comparable to exponentially
growing parasites (44% labeling), while the others are either dead or in some kind of
arrest. We sought to differentiate between these models by plotting the percent of parasite
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clusters as a function of the percent BrdU-labeling within those clusters. Assuming that
the parasites are replicating homogeneously, we would anticipate a distribution of percent
labeling centered at the mean. Acute-phase parasites fit this model, with 61% of all
clusters showing between 21% and 70% labeling. In contrast, persistent parasites do not
show a single distribution centered at 19% labeling, but rather appear to have two peaks
representative of two different types of clusters (Figure 2C). The first type, which
accounts for ~60% of the total clusters, is not labeled with BrdU during the duration of
the experiment. The other population had a mean labeling frequency of 57 ± 21% (N =
2E/5M/170P/50 clusters). This second population resemble acute phase parasites (mean
labeling frequency of 46 ± 29%; N = 2E/5M/585P/77 clusters). While this analysis
strongly suggests the existence of a poorly-replicating sub-population, it excludes data
from parasites not in ‘clusters’, which account for ~20% of all persistent parasites. We
thus re-analyzed the above data, plotting percent BrdU labeling as a function of the
number of parasites per infected cell. Assuming homogeneous parasite replication,
roughly 44% of acute-phase and 19% of persistent parasites should be BrdU+, regardless
of the number of parasites per host cell. The data from acute-phase parasites very closely
matches this prediction, with 40-50% BrdU-labeling independent of the number of
intracellular parasites (N = 2E/5M/976P/176 infected cells). However, once again the
persistent parasite data do not fit a homogeneous replication model. ~12% of the parasites
in host cells containing 1 to 3 parasites are BrdU+, while ~46% of the parasites within
‘clusters’ containing 4 or more parasites are BrdU+ (Figure 2D; N = 2E/6M/379P/167
infected cells). These results suggest that a population of host cells contain persistent
parasites that replicate similarly to acute phase parasites, whereas another population of
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host cells contains parasites that replicate poorly. This second population is not apparent
in acutely infected mice.
Persistent parasites predominantly reside in macrophages and dendritic cells
We also sought to determine the localization of persistent parasites. Footpad and lymph
node sections were stained to detect L. major nuclei and host cell-type specific markers.
At least three cell types have been proposed as hosts for persistent parasites: fibroblasts,
macrophages, and dendritic cells (25-27). Here, we define fibroblasts as cells that are
recognized by anti-ER-TR7 antisera, dendritic cells (DCs) as cells expressing CD11c
(either F4/80+ or F4/80-), and macrophages as F4/80-positive, CD11c-negative cells. For
this and other experiments, confocal microscopy allowed us to ensure that persistent
parasites were actually ‘within’ the host cells, as we could visualize the host cell plasma
membrane or cytoplasm (depending on the antibody used) in the X, Y, and Z planes.
Only 2 ± 3% of persistent parasites in footpad tissue and 10 ± 7% of persistent parasites
in lymph nodes were within are within ER-TR7+ host cells (footpad N = 3E / 6M / 528P;
lymph node N = 2E / 4M / 191P), despite the presence of numerous ER-TR7+ cells in
each field from both sites. In contrast, 80 ± 6% of footpad persistent parasites and 87 ±
12% of lymph node persistent parasites were found within F4/80+ cells in tissue (footpad
N = 3E / 8M / 983P; lymph node N = 2E / 4M / 208P). 13 ± 2% of persistent footpad
parasites and 61 ± 19% of lymph node parasites were within CD11c+ cells (footpad N =
3E / 8M / 1074P; lymph node N = 2E / 4M / 208P; Figure 3A and B). By dual-staining
sections to simultaneously detect L. major histone proteins, CD11c, and F4/80, we found
that 78 ± 9% of footpad persistent parasites were within F4/80+CD11c- macrophages, and
16 ± 6% were within F4/80+CD11c+ DCs in footpad tissue (N = 2E / 4M / 266P). In
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lymph nodes, 30 ± 18% of persistent parasites were within F4/80+CD11c- cells, and 61 ±
19% were within F4/80+CD11c+ DCs. Importantly, essentially all footpad persistent
parasites (97 ± 3% in footpads and 91 ± 5% in lymph nodes) imaged in this experiment
were labeled with one or both markers, showing that almost all persistent parasites are
within macrophages and dendritic cells at both sites (with ~10% of lymph node parasites
in ER-TR7+ fibroblasts) and that a major host cell type was not missed (Figure 3C).
The distribution of persistent parasites suggests intracellular replication in both
macrophages and dendritic cells
We used the “parasite cluster” analysis described above to address where parasite
replication takes place. Similar to the distribution of total persistent parasites within host
cell types in footpads, 74 ± 5% of parasite clusters occurred within host cells expressing
F4/80, while 17 ± 5% were within CD11c+ cells. These data suggest that the intracellular
replication takes place within both macrophages and dendritic cells as the percentage of
parasite clusters within F4/80+ cells (which include CD11c+ cells) greatly exceeds the
percentage of clusters within CD11c+ cells (Table 2). We plotted the percent of infected
cells expressing CD11c as a function of the number of parasites per cell to determine if
dendritic cells preferentially harbor the ‘static’ sub-population which tends to be within
host cells containing <3 parasites but did not see any obvious correlation (Supplementary
figure 2A; N = 3E/8M/283P/124 infected cells.)
Macrophages infected with persistent L. major in footpad tissue do not express markers
of alternative activation.
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We hypothesized that some F4/80+ cells containing persistent L. major may be
alternatively activated macrophages and that these cells may provide a favorable
environment for parasite survival. To test this, we stained footpad sections from
persistently infected mice to detect parasite histones, F4/80, and RELMα (a marker of
alternatively activated macrophages) (28, 29). As above, the majority of persistent L.
major were within F4/80+ cells (96 ± 2%), but none of these infected cells expressed
RELMα (N = 2E/3M/284P). Positive controls included the visualizing of F4/80+RELMα+
cells elsewhere in the same tissue sections and the ability of the anti-RELMα antibody to
yield 70-80% positive cells in alternatively activated macrophages obtained by IL-4 and
IL-13 treatment of peritoneal macrophages (Supplementary figure S1). These data
suggest that persistent parasites do not favor alternatively activated macrophages as a site
of replication.
Most persistent L. major are found within iNOS+ macrophages and dendritic cells
The finding that persistent parasites replicate suggests that they must also be destroyed,
or else parasites number would increase. Nitric oxide (NO), generated from L-arginine
via iNOS, is essential for the control of L. major in vivo, and as such, it has been assumed
that L. major is killed within iNOS-expressing host cells (3, 4, 30). Thus we asked
whether some fraction of persistent parasites was found within iNOS+ host cells and
whether it is within these cells that the parasites are destroyed. 59 ± 15% of persistent
parasites in footpads were found within iNOS-expressing cells (N = 3 E / 8M / 2535P).
In addition, 80 ± 19% percent of persistent lymph node parasites are within iNOS+ cells
(N = 2E / 4M / 477P), in agreement with previously published data (30).
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Both of the major persistent parasite-harboring host cell types (macrophages and
dendritic cells) were found to express iNOS when infected with persistent L. major. 10 ±
6% of total persistent parasites were found within CD11c/iNOS double positive cells
(Figure 4A; N = 3E / 8M / 1074P). As our instrument can capture at most 3-color images,
we were unable to simultaneously visualize parasites with F4/80, CD11c, and iNOS.
However, the fact that the percentage of parasites within F4/80+iNOS+ cells (42 ± 14%; N
= 3 E / 8M / 983P) is more than 3 times the total fraction of parasites within CD11c+ cells
argues that many of the F4/80+iNOS+ cells were macrophages (Figure 4B).
Persistent L. major survive and replicate within iNOS-expressing cells
We asked next whether the persistent parasites seen in iNOS+ cells showed evidence of
destruction. First, we evaluated whether the parasites in iNOS-expressing host cells were
morphologically intact. The parasites used in these experiments express GFP, allowing
the parasite cytoplasm within host cells to be clearly delineated using a chicken anti-GFP
antibody while iNOS expression is simultaneously visualized using a rabbit anti-iNOS
antibody. In these studies, parasites within iNOS+ host cells were morphologically
normal and indistinguishable from persistent parasites within iNOS- host cells, suggesting
that the parasites in iNOS-expressing cells are intact (Figure 4C). In addition to overall
cellular morphology, the integrity of the parasite’s nuclear genome is a good marker for
parasite viability (31). Of the 80 parasite nuclei visualized in these experiments with the
anti-histone antisera, 79 were within iNOS+ cells. However, none of these parasite nuclei
had TUNEL+ nuclei regardless of their localization within iNOS+ or iNOS- cells (Figure
4D; N = 2E/3M/80P). In contrast to the result for nuclear DNA integrity, a population (26
± 15%) of persistent parasites had TUNEL+ kinetoplast DNA. As kinetoplast replication
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involves the transient formation of double-stranded breaks that are recognized by the
TUNEL reaction (32), this may be expected of healthy cells.
To determine if parasite replication was taking place in iNOS+ cells, we determined if
parasites within iNOS expressing cells incorporate BrdU. We stained tissue sections from
persistently-infected mice that had been injected with BrdU (as described above) to
simultaneously detect parasite histones, BrdU, and iNOS. In these sections, 82 ± 10% of
the parasites were within iNOS+ cells, slightly higher than that seen in other experiments
(P = 0.03 by the Student’s t-test). 85 ± 13% of the BrdU+ parasites were within iNOS+
cells, suggesting that persistent parasite replication does not preferentially occur within
iNOS- host cells (Figure 4E and Table 1, N = 2E / 3M / 254P)
To further examine if persistent parasites replicate within iNOS-expressing cells in vivo,
we used the indirect assay of replication looking for “parasite clusters” within iNOS
expressing cells and found that 61 ± 9% of persistent parasites “clusters” (Table 1, N =
3E / 8M / 329 clusters) occurred within cells expressing iNOS. The percent of parasites
within iNOS+ cells does not obviously correlate with the number of parasites per infected
cells (Supplementary figure 2B; N = 3E/8M/305P/137 infected cells), suggesting that
neither the fast-replicating nor poorly-replicating sub-population of parasites are
preferentially found within these cells. Taken together, these data show that infected
iNOS-expressing cells may be at least transiently permissive host cells for persistent
parasites.
Persistently infected cells express high levels of iNOS
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One explanation for the apparent survival of persistent parasites within iNOS+ cells might
be that the level of iNOS expression by persistently infected cells is lower than that of
cells which generate lethal levels of NO. To test this, we compared the iNOS staining
intensity between persistently infected iNOS+ cells with that of interferon-γ/LPSactivated PEMs, which kill L. major in an iNOS-dependent manner (33). Quantitation of
iNOS staining intensity per cell area showed that in vivo persistently infected host cells
actually expressed higher relative iNOS levels than did the activated PEMs in vitro
(Figure 5; 1.6 fold higher average fluorescence intensity; P < 0.001 by Student’s t-test).
Thus reduced iNOS expression cannot account for the survival of persistent parasites in
iNOS+ host cells, suggesting that the cells containing persistent parasites in vivo express
sufficient iNOS to generate leishmanicidal levels of NO.
Neither host nor parasite arginase is up-regulated in association with infected iNOSexpressing host cells
iNOS mediated NO synthesis requires arginine, and depletion of arginine through the
action of arginase in infected or neighboring cells could serve to limit NO production
despite high levels of iNOS (34). Mice synthesize two isoforms of arginase which differ
in their sub-cellular localization: Arg1 which is cytoplasmic, and Arg2, which is
mitochondrial (35). Parasite infected host cells were visualized using anti-histone antisera
and scored for iNOS+ and arginase(1 or 2)+; additionally, we scored whether adjacent
cells (defined as in physical contact with the parasite-infected cell) were arginase+. We
chose to look at cells ‘adjacent’ to the infected cell because some arginase-expressing
cells are thought to deplete arginine in their immediate vicinity (36, 37). In these
experiments 83 ± 14% of persistent parasites were within iNOS expressing cells,
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however only 3 ± 3% were within cells that simultaneously expressed iNOS and Arg1,
and only 12 ± 11% of WT persistent parasites within iNOS+ cells were adjacent to an
Arg1+ host cell (Figure 6A). Pooling these data we find that 15 ± 14% of persistent
parasites within iNOS-expressing cells are either within or adjacent to an Arg1+ cell (N =
3E / 5M / 317P). We did not detect any persistent footpad parasites within iNOS+ cells
that were also within or adjacent to Arg2+ host cells (N = 2E / 2M / 175P) despite seeing
regions of intense Arg2 staining elsewhere in the tissue (all of which were > 75 microns
from parasites) indicative of proper Arg2 reactivity (data not shown).
While L. major also have an arginase gene, promastigotes do not appear to express
sufficient arginase to affect NO production by activated macrophages in vitro (18, 38).
However, persistent parasites may express higher levels of arginase. We stained in
parallel L. major promastigotes and footpad tissue sections from persistently-infected
mice to detect parasite histones and parasite arginase and compared their relative arginase
staining intensity on a per-cell basis (Figure 6B and C). We find that most, if not all,
persistent parasites express some level of arginase (N = 2E / 2M / 65 P). However, the
mean relative arginase fluorescence intensity of promastigotes was 2-fold higher than that
of persistent parasites when differences in background fluorescence are taken into
account (P = 10-6 by the Student’s t-test), suggesting that L. major do not up-regulate
arginase during the persistent phase of the infection (Figure 6D).
Amastigotes are more resistant to NO than metacyclics within activated macrophages in
vitro
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Our findings that persistent parasites within iNOS+ host cells appear viable was
surprising and suggested that persistent parasites may be more tolerant of NO than
promastigotes. As a surrogate for persistent parasites, we sought to compare the NO
tolerance of amastigotes with that of metacyclic promastigotes in vitro. As expected,
metacyclic-stage parasites were rapidly killed in an within peritoneal macrophages
(PEMs) that had been pre-treated with interferon-γ and LPS, with 10-fold fewer parasites
surviving 24 hours after infection than parasites added to untreated PEMs (Figure 7A; P
< 0.05). Treatment of activated PEMs with the specific iNOS inhibitor L-NIL (39)
reduced the parasite mortality showing that parasite killing is iNOS-dependent (Figure
7A). In contrast, parasite killing by activated macrophages was greatly reduced when
metacyclic-stage L. major were allowed to infect PEMs for 72 hours (in which time they
differentiate into amastigotes and begin to replicate) prior to the addition of interferon-γ
and LPS. Under these conditions, 94 ± 17% of the parasites remain 24 hours after host
cell stimulation despite the production of substantial quantities of NO by the stimulated
macrophages. Relative to unstimulated controls or cells stimulated in the presence of LNIL (in which the parasite number continues to increase) there is a 1.5-fold reduction in
parasite titers in the stimulated PECs (Figure 7B). These data suggest that amastigotes are
substantially more tolerant of NO than are promastigotes (94% versus 6% survival; P <
0.001 by the Student’s t-test).
Attenuated lpg2- L. major resembles WT persistent parasites in most respects
L. major parasites lacking the LPG2 gene (lpg2-) are a proposed model of Leishmania
persistence (12). We sought to determine the cell types infected by lpg2- in footpad tissue
and whether these parasites replicate in vivo. Because lpg2- appears to enter a
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persistence-like state almost immediately, we performed most experiments 1 month after
infection (versus 5 or more months post infection with WT parasites). At this time point,
lpg2- resembled WT persistent parasites for most of the parameters tested above (Table
2). Among these WT persistent parasites and lpg2- were indistinguishable from each
other in terms of the percent of parasites labeling with BrdU, the percent of parasites
within F4/80+ cells, and the percent of parasites found within iNOS+ host cells. Like
persistent WT parasites, lpg2- parasites were not found within cells labeled with the
markers ER-TR7, RELMα, nor cells that express high levels of Arg2. In addition lpg2-,
like WT persistent parasites, replicate within iNOS-expressing cells by both BrdU and
cluster analysis.
More lpg2- parasites are within dendritic cells or associated with Arg1+ cells than
persistent WT
We found two differences between the phenotype of cells infected with lpg2- versus
those infected with persistent WT parasites (Table 2). First, the frequency of lpg2- within
CD11c+ cells was elevated 3-fold relative to WT persistent parasites (46 ± 29%, P <
0.006; N = 3E / 10M / 1004P). Among the lpg2- -infected mice, there appears to be a
bimodal distribution of parasites within CD11c+ cells (in one group, <40% of the
parasites are within CD11c+ cells, while in the other, >60% of the parasites are within
these cells). Both of these groups were present in all experiments. We also looked to see
if either group was associated with higher expression of iNOS relative to the other group,
but found no obvious correlation.
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There was also a clear difference between WT and lpg2- parasites in terms of their
association with Arg1. 37 ± 41% of lpg2- parasites were found in iNOS+/Arg1+ host cells
with another 35 ± 32% found in iNOS+ host cells adjacent to an Arg1+ host cell. In total,
72 ± 26% of persistent footpad lpg2- parasites were associated with Arg1 expression
which is roughly 5-fold higher than WT (P = 0.002, N = 3E / 5M / 477P).
Differences between the cell association of persistent WT and lpg2- parasites are not due
to the duration of infection
The observed differences between the two parasite lines could result from differences in
the duration of infection (e.g. one month for lpg2- versus >5 months for persistent WT).
Thus, we compared the association of lpg2- parasites one month after infection with that
of lpg2- 5 months after infection focusing on their association with CD11c and Arg1. 78
± 13% of lpg2- parasites are within CD11c+ DCs 5 months after infection (Figure 8A; N
= 2E / 5M / 520P). This is 6-fold higher than what is observed for persistent WT (P < 106

) and 1.7-fold higher than lpg2- at one month (P = 0.03). In addition, 85 ± 12% of lpg2-

parasites within footpad tissue 5 months after infection are either within or directly
adjacent to a cell expressing Arg1 (Figure 8B; N = 2E / 5M / 901P). Although this was
indistinguishable from lpg2- at one month post-infection (68 ± 27%), it is 5-fold higher
than persistent WT (P < 10-3). Taken together, these data suggest that the differences
observed between persistent WT and lpg2- are not the result of differences in the duration
of the infection but are more likely due to differences in the interactions between the two
parasite lines and the host.
Association with Arg1 negatively correlates with the ability of lpg2- to vaccinate mice
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Unlike WT persistent parasites, lpg2- does not vaccinate C57BL/6 mice without the use
of CpG DNA as an adjuvant (40). We asked whether the observed differences between
lpg2- and persistent WT correlate with the relative inability of lpg2- to vaccinate mice of
this strain. To address this, we investigated the association of lpg2- parasites and host
cells expressing these proteins in BALB/c mice, which become highly immune to L.
major infections following vaccination with lpg2- (14). The percent of lpg2- within
CD11c+ cells in BALB/c mice is indistinguishable from that of lpg2- in C57BL/6 mice
(44 ± 21% versus 46 ± 29%; N = 2E / 10M / 745P), and significantly higher than what is
seen for WT persistent parasites (Figure 8A; P = 0.001). Thus, the presence of lpg2parasites within CD11c+ dendritic cells does not correlate with the ability of the parasite
to vaccinate its hosts.
On the other hand, the association of lpg2- with host Arg1 expression does change
depending on its ability to vaccinate mice. Unlike lpg2- within C57BL/6 mice, in which a
relatively high percentage of the parasites (72%) are either within or adjacent to an Arg1expressing cell, only 16 ± 25% of lpg2- in BALB/c mice is associated with Arg1 (Figure
8B; P < 0.005; N = 2E / 9M / 1105P), and are thus indistinguishable from WT persistent
parasites in a C57BL/6 mouse. These data suggest that Arg1 expression may be a
negative correlate of L. major immunity.
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Discussion
Replication and localization of persistent L. major
In this study, we examined the localization of persistent L. major in the footpad
inoculation site and the draining lymph node. At both sites, parasites were
overwhelmingly found within either F4/80+CD11c- macrophages or F4/80+CD11c+
dendritic cells with ~10% of lymph node persistent parasites within ER-TR7+ reticular
fibroblasts. A high percentage of both infected macrophages and dendritic cells expressed
iNOS in lymph node and footpad tissue.
Because the number of persistent parasites remains roughly constant over time, it has
previously been difficult to determine whether these parasites are replicating or not, as
constant populations could result from either a long-lived, non-replicating form of the
parasite or continual parasite replication and destruction. Traditional methods for
determining parasite replication in vivo (such as limiting dilution assays) cannot
distinguish between these two scenarios. We therefore developed a BrdU-incorporation
assay to detect parasite replication in vivo. Using this assay, we found for the first time
that persistent parasites do indeed replicate in footpad tissue.
Identification of fast-replicating and poorly-replicating subpopulations
Interestingly, persistent parasites showed about 2-fold less BrdU incorporation than
acute-phase parasites after a 24 hour labeling period. Further analysis of our data
identified two populations of host cells. The first population is characterized by a low
number of intracellular parasites (less than 3) and a low percentage of BrdU-labeling
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(~12%) while the other population had a larger number of intracellular parasites and
BrdU-labeling comparable to acute-phase parasites (46%). These data suggests that there
are either two populations of parasites based on their relative replication or two
populations of host cells based on their relative ability to permit parasite replication. As
the poorly-replicating population of parasites tends to be within host cells containing 1-3
parasites, we looked to see if cells expressing CD11c or iNOS were correlated with
relatively low intracellular parasite burdens, but we found no obvious association.
Another question is whether or not the poorly replicating parasites are alive and in some
sort of stasis or are dead/dying. While current technologies do not allow us to definitively
answer this question, we favor the model that the poorly replicating parasites are alive
because we were unable to detect any parasites that were morphologically abnormal or
that had degraded DNA. Further suggesting that these parasites are alive, parasites killed
intracellularly are digested by the macrophage and disappear rapidly (31) and therefore
would be difficult to find.
Our finding that a large percentage of persistent L. major is in a non-replicating state fits
in well with data from other organisms which cause life-long asymptomatic persistent
infections. Herpes viruses, which express only a few select transcripts during latent
infections (41), are probably the best example of a pathogen that has adopted a strategy of
quiescence to facilitate persistence. In addition, Toxoplasma gondii persist within their
host in the poorly replicating bradyzoite stage (42), and a population of persistent
Mycobacterium tuberculosis are proposed to be in a quiescent ‘persister’ state (43).
Presumably, quiescence helps these pathogens avoid the immune response and increase

102

their antimicrobial tolerance. Leishmania may be benefited in the same ways, which may
explain the difficulty of achieving a sterile cure of persistent infections (44).
With the exception of persistent Leishmania, the quiescent forms of the pathogens listed
above are known to have distinct gene expression profiles from the actively replicating
forms (45-47). It is not yet known whether or how the quiescent persistent parasites differ
from the replicating persistent parasites or if persistent parasites in general differ from
acute-phase amastigotes. Future studies comparing the gene expression profiles of
persistent parasites with acute phase parasites, as well as quiescent persistent parasites
(enriched in small clusters) versus replicating persistent parasites (enriched in large
clusters) will be crucial to see if Leishmania also has a stage of its life cycle that is
specifically devoted to persistence.
Persistent parasites within iNOS-expressing cells appear healthy
As NO-synthase activity is an essential component of L. major killing by activated
macrophages in vitro (33) and in the control of experimental leishmaniasis by resistant
mice (3, 48) we postulated that iNOS-expressing cells were sites of parasite destruction.
Surprisingly, however, the parasites that we observed within these cells were not
‘corpses’ but rather were morphologically normal and had intact nuclear genomes as
determined by TUNEL staining. Furthermore, these parasites appeared to be replicating
both by the ‘parasite cluster’ criteria and by BrdU-incorporation data. Taken together,
these data suggest the parasites we observed within iNOS-expressing cells were at least
transiently viable.
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Our data therefore raise the question of whether these infected iNOS-expressing cells
generate lethal amounts of NO. The level of iNOS protein within persistently infected
cells is comparable to that of interferon-γ/LPS-treated peritoneal macrophages, which
produce lethal amounts of NO, suggesting that the capacity of persistently infected cells
to generate NO is not limited by insufficient iNOS expression. Although we cannot
measure the levels of reactive nitrogen within infected iNOS-expressing cells in vivo, we
can look at known pathways that may attenuate iNOS activity; one of which being the
arginase pathway. This pathway could potentially compete with iNOS for its substrate
(L-arginine), resulting in less nitric oxide production. As mentioned above, very few WT
persistent parasites within iNOS-expressing cells are associated with elevated levels of
Arg1 expression and we see no association of persistent parasites with elevated levels of
Arg2. As such, it is unlikely that either isoform of host arginase attenuates the ability of
iNOS-expressing cells to generate NO. In addition to Arg1 and Arg2, L. major express
their own arginase. However, the arginase activity within L. major is extremely low in
vitro and does not appear to impact the amount of NO produced by classically activated
macrophages infected with promastigote-stage parasites (18, 38) . Using antibodies
specific to parasite arginase, we show that persistent parasites (most of which were within
iNOS-expressing cells) do not increase arginase expression relative to promastigotes,
suggesting that parasite arginase is not an anti-iNOS defense mechanism. Furthermore,
preliminary data show that arg- L. major are capable of persistence within resistant mice
following healing (J. Uzonna, personal communication). Based on these data, it seems
unlikely that parasite-derived arginase affects the capacity of host cells to generate NO.
While there may be other mechanisms, such as aggresome formation or iNOS miss-
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localization, by which high levels of iNOS are expressed without the parasites
experiencing high levels of NO (49-51), we saw no evidence of such mechanisms in our
samples and, as such, we suspect that at least some if not all iNOS-expressing cells are
capable of generating large quantities of NO. Survival of persistent parasites within such
cells would suggest that persistent parasites are more resistant to the ill effects of NO
than are promastigotes. Indeed, our in vitro studies show that amastigotes are
substantially more resistant to NO than are promastigotes.
Comparison of WT persistent and lpg2- identified arginase 1 as a negative correlate of
immunity
One of the aims of this work was to compare the candidate vaccine line lpg2- with WT
persistent parasites: the gold standard in anti-Leishmania vaccines. Previous work has
shown that lpg2- L. major differs from WT parasites in terms of its ability to survive
within macrophages in vitro and to cause pathology in vivo. However, it resembles WT
persistent parasites since it is found in mice in numbers comparable to WT persistent
parasites (12) and can vaccinate susceptible (BALB/c) mice against virulent challenge
(14). Here, we found that lpg2- was indistinguishable from WT persistent parasites in
most respects. Like persistent WT, lpg2- parasites are not found within ER-TR7+ cells
but do infect macrophages and DCs, some of which express iNOS. In addition, our
preliminary data also suggests that lpg2- recruits Foxp3+ cells to the site of infection in
BALB/c mice (data not shown), a phenomenon that is also reported for persistent WT
parasites (11). Finally, lpg2- and WT persistent parasites are indistinguishable in terms of
replication, most of which takes place within iNOS expressing cells. Taken together,
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these data continue to support the use of lpg2- parasites as a model of Leishmania
persistence.
However, our work has also demonstrated clear differences between WT persistent
parasites and lpg2-. In particular, significantly more lpg2- parasites were within DCs and
are associated with Arg1 expression in the footpads of C57BL/6 mice than is the case
with WT persistent parasites. We ruled out the possibility that these differences are the
result of differences in the duration of the infection as the association of lpg2- parasites
with CD11c and Arg1 in mice infected for more than 5 months more closely resembles
that of lpg2- at one month post-infection than WT persistent parasites. Instead, these
differences are likely related to differences in the mouse’s immune response to the two
parasite lines, and may correlate with the inability of lpg2- to vaccinate resistant
(C57BL/6) mice without the addition of CpG DNA as an adjuvant (40). Indeed, we found
that the association of lpg2- and host Arg1 correlate inversely with the ability of lpg2- to
vaccinate its host, as lpg2- parasites within BALB/c mice (which are protected by
vaccination with lpg2-) more closely resemble persistent WT than lpg2- in a C57BL/6
mouse with regards to Arg1 association. Whether the increased association of parasites
with Arg1 results from or is causative of conditions leading to vaccine failure remains
unknown. However, Arg1, along with iNOS, can lead to arginine-depleted
microenvironments which have strong inhibitory effects on both T-cell proliferation and
function and induce regulatory T-cell differentiation (36, 52). In fact, arginine depletion
has been shown to impair Leishmania-specific T-cell responses (53). In addition,
products of Arg1 activity such as urea and polyamines may also have immunosuppressive
effects (54-56). Thus, the up-regulation of Arg1 in lpg2- -infected C57BL/6 mice
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provides a viable explanation for why the immunity generated by this attenuated parasite
line is weak in these mice.
Models of L. major persistence
It has long been assumed that persistent L. major required “safe cells” to evade lethal
nitric oxide that would otherwise result in parasite clearance. Two cell types, ER-TR7+
reticular fibroblasts and alternatively activated macrophages have been implicated as
such “safe cells” as they do not express high levels of iNOS (25, 26). However, as
mentioned above, the persistent L. major found within iNOS+ cells are apparently healthy
by all criteria tested. As such, a cell’s capacity to express high levels of iNOS protein
may not be a good indicator of how “safe” that cell would be for persistent parasites.
In addition, if the parasites do indeed require safe cells, then such cells should be found at
all sites of parasite persistence (i.e. the site of inoculation and the lymph node draining
that site). Although our data is in agreement with the published literature about the
presence of a population of persistent parasites within ER-TR7+ fibroblasts in lymph
nodes, we find little, if any, association of persistent L. major with this marker at the site
of inoculation (the footpad). Instead, we find that the vast majority of the parasites in
both footpad and lymph node tissue are within macrophages and dendritic cells. Further
investigation revealed that infected macrophages do not express RELMα, a marker of
alternative activation, and instead expressed iNOS, a marker of classical activation that is
repressed in alternatively activated macrophages (29). While these data do not exclude
the possibility that there is a “safe cell type” that serves as a reservoir for persistent L.

107

major, they demonstrate that neither reticular fibroblasts nor alternatively activated
macrophages are major reservoir host cell types for parasite persistence.
Our data suggest an alternative model of L. major persistence (Figure 9). We have shown
that a population of persistent parasites replicate comparably to acute-phase parasites.
However, despite substantial replication by these parasites, the parasite number remains
roughly constant, thus implying that parasite replication is offset by parasite killing. In
this model, the offspring of replicating parasites infect new host cells where they have
three potential fates. They may either continue active replication, become ‘static’ or be
destroyed. How the eventual fate of the parasites is decided is not known and may be
either stochastic or depend on the phenotype of the host cell infected.
A stem immunogen model of concomitant immunity
The constant replication and destruction of persistent Leishmania may help explain the
concomitant immunity induced by either persistent WT or lpg2- parasites. While
replicating or static parasites likely have roles in perpetuating the infection, killed
parasites might be a good source of antigen that could be presented to the immune
system, maintaining a robust anti-Leishmania response. This assumption is reasonable, as
antigens from dead parasites can be presented to the immune system whereas live
parasites have been shown to inhibit antigen presentation by their host cell (57-59). As
parasite replication and destruction would be a continual process in a persistently infected
host, such constant boosting would result in the life-long immunity observed in healed
Leishmania patients. Thus, from the host’s perspective, persistent parasites serve as a
continually self-renewing vaccine.
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In some respects, the model we propose here is comparable to stem cell biology (Figure
9). Like stem cells, persistent L. major are capable of distinct fates: either selfregeneration or ‘differentiation’ into a cell that has functional consequences which in this
case is death and immune stimulation. Here, the replicating parasites represent a
continually self-renewing “stem” with some of the progeny parasites surviving either as
replicating or quiescent forms. However, many of the progeny parasites become
‘terminally differentiated’ within antigen presenting cells, which could result in immune
stimulation. Modulations of the host’s immune response would affect the flux of parasites
going down one pathway versus the other, resulting in reactivation or sterile cure as
extremes (4, 11).
The stem immunogen model relies on the assumption that immune stimulation results
from the presentation of antigens derived from killed persistent parasites, a point that has
not been established. In fact, although in vitro data suggest that parasite killing may be a
prerequisite for the presentation of antigens found within the parasite’s cytoplasm (60)
and it is well established that live Leishmania inhibit antigen presentation by their host
cells (57-59), it is possible that live parasites, rather than those that are being destroyed,
are responsible for the persistent parasite-dependent immune stimulation and
maintenance of immunity. Thus, an important future question is what host cells present
Leishmania antigens: those that contain viable parasites or those that have previously
killed parasites. In this study, we were unable to find the latter class of host cells, and so
new approaches will be required to properly address this question.
If supported by further studies with persistent Leishmania, the stem immunogen model of
concomitant immunity could also be proposed for other persistent pathogens such as
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Toxoplasma gondii and herpesviruses. Both persist indefinitely while conferring life-long
protective immunity against pathology associated with re-infection. In addition, there is
evidence of at least sporadic sub-clinical reactivation from the persistent/latent stage of
the infection which would result in the production of antigens for immune stimulation
(61, 62). Currently, it remains unknown whether these sub-clinical reactivations have a
role in maintaining immunity or even whether persistent Toxoplasma or latent herpes
virus infections are required for immunity. However, there is some evidence that at least
partial reactivation is required to elicit protective immunity against herpesvirus challenge.
Whereas a replication-deficient γHV68 (ORF50STOP) with a block in immediate early
gene expression established latency but failed to protect mice from a challenge from WT
virus (63), a latent attenuated virus (ORF31STOP) capable of partial reactivation
involving immediate early and early gene expression stimulated robust cellular immunity
to WT challenge (64), potentially by continually boosting the host’s immune response.
The fact that live attenuated vaccine lines that can persist and at least partially replicate
(e.g. L. major lpg2- or γHV68-ORF31STOP) can effectively vaccinate their hosts while
those that do not partially replicate (e.g. L. major dhfr-ts or γHV68-ORF50STOP) are
much less effective suggests that the best vaccines may be those consisting of an
attenuated pathogen capable of long term persistence and replication/reactivation but
incapable of causing pathology. Such a vaccine may have the added benefit of conferring
protection to other pathogens as well (2).
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Figure legends
Figure 1. BrdU-incorporation assay with Leishmania. A. Graph comparing parasite
growth as promastigotes in culture media containing BrdU with BrdU-incorporation.
Data shown is one of three experiments. B. The percentage of BrdU-positive acute-phase
parasite nuclei after 1, 3, or 6 doses of BrdU in a 24 hour period. Data shown is from one
experiment, with three mice per treatment. Error bars represent standard deviation. C.
Representative image of six persistent parasite nuclei (red), two of which are BrdU+
(green). Nuclei are stained blue. Scale bar indicates 5µm. D. The percentage of BrdU+
parasite nuclei for acute and persistent L. major. Horizontal bars represent the mean for
all mice. P value was determined by the Student’s t-test.
Figure 2. Distribution of persistent parasites within host cells. A. The number of infected
host cells is plotted as a function of the number of parasites per host cell. ~83% of cells
infected with persistent parasites contain 3 or less parasites. B. The number of persistent
L. major plotted as a function of the number of parasites per infected host cell. 78% of
parasites are within host cells containing 2 or more parasites (‘clusters’). C. Percent of
acute- or persistent-phase ‘clusters’ (host cells containing 2+ parasites) as a function of
the percent BrdU-positivity within each cluster. D. Percent BrdU-positivity of acute- or
persistent-phase parasites as a function of the number of parasites per infected cell.
Numbers within bars represent the number of infected cells scored for each category.
Figure 3. Association of persistent parasites with the markers ER-TR7, F4/80, and CD11c
in footpads and lymph nodes. A. Representative pictures of persistent parasites from the
footpad (top) or lymph node (bottom) with the markers ER-TR7, F4/80, CD11c
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individually and F4/80 and CD11c in combination (far right). Parasites are detected with
a pool of antibodies raised against L. major histone proteins (green). Cell-type markers
are depicted in red, except for F4/80 in the far-right panel, which is depicted in blue.
Scale bar indicates 5µm. B. The percentage of persistent parasites within cells expressing
each marker individually in footpads (FP) or lymph nodes (LN). Each data point
represents one mouse, and horizontal bars represent the mean for all mice. C. The
percentage of persistent parasites within macrophages (CD11c-F4/80+) and dendritic cells
(CD11c+F4/80+/-) in footpads and lymph nodes.
Figure 4. Persistent L. major survive and replicate within iNOS-expressing cells. A and
B. Persistent parasites nuclei (green) within an iNOS-expressing (blue), CD11c+ (red, A)
or F4/80+ (red, B) host cell. C. A persistent GFP-expressing parasite (green) within an
iNOS-expressing host cell (red). Nuclei are stained blue. The parasite appears intact. D.
Persistent parasites within an iNOS-expressing cell have intact nuclear genomes. Parasite
nuclei were detected with antibodies against histone proteins (green), degraded DNA is
detected by TUNEL-staining (red), and iNOS is stained blue. Absence of co-localization
of nuclei and TUNEL-staining shows that parasite nuclear genomes are intact. Some
parasites (white arrows) had TUNEL+ kinetoplasts which would be expected even in
healthy parasites. Scale bar indicates 5 µm. E. Persistent parasites incorporate BrdU in
iNOS expressing cells. Parasite histone proteins are stained green, BrdU is stained red,
and iNOS is stained blue. All three parasites are within an iNOS+ cell and are BrdU+.
Scale bar indicates 5 µm.
Figure 5. Comparison of iNOS expression levels by macrophages activated in vitro and
cells infected with lpg2- parasites in vivo. A. Representative image of starch elicited
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peritoneal macrophages that were cultured in the presence of interferon-γ and LPS for 24
h and then stained to detect parasite histones (green) iNOS (red) and nuclei (blue). These
cells were not infected with L. major. B. Representative image of an infected cell in
footpad tissue stained identically to the cells in ‘A’. Images of activated macrophages in
vitro or iNOS-expressing infected cells from footpad tissue were captured by confocal
microscopy using identical settings. Scale bar indicates 5 µm. C. Comparison of average
red (iNOS) fluorescence intensity per µm2 within in vitro activated peritoneal
macrophages (PEM) or iNOS-expressing infected cells from footpad tissue. Each data
point represents one cell. Black horizontal bars represent mean for all cells. The average
background intensity is represented by the grey horizontal line. P < 0.001 by the
Student’s t-test.
Figure 6. Association of persistent parasites with Arg1 expression. A. Representative
image of footpad tissue from mice infected with persistent L. major showing an infected
iNOS+ cell (blue) adjacent to an Arg1+ (red) cell. Parasite nuclei are stained green. B.
Representative image of log-phase promastigotes stained to detect histones (green) and
arginase (red). C. Representative image of persistently-infected footpad tissue stained
identically as the parasites in (B). Scale bar equals 5 microns. D. Analysis of images
showing relative fluorescence intensity of persistent parasites and promastigotes. This
value was determined by measuring the sum “red” (arginase) intensity within a circle
with a 2.28 micron radius centered on the parasite nucleus on confocal images such as
those in (A) and (B) in which the confocal stack had been compressed into a single plane.
Grey horizontal bars represent the average background, black bars represent the mean
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arginase reactivity for all cells. Each data point represents one parasite. *** represents P
< 10-6 by the Student’s t-test.
Figure 7. Amastigotes are more resistant to NO than are metacyclic-stage parasites. A.
Nitrite production (left side) and percent parasite survival (right side) 24 hours after
infection of control peritoneal macrophages, macrophages activated with interferon-γ and
LPS, or activated macrophages treated with the iNOS inhibitor L-NIL. B. Nitrite
production and percent parasite survival measured at 96 hours post-infection and 24
hours after the addition of interferon-γ and LPS with or without iNOS inhibitor. For all
plots, the data shown is the average of three independent experiments, and error bars
represent standard deviation.
Figure 8. Comparison of the association with CD11c and Arg1 between WT persistent
parasites, lpg2- 1 month after infection in C57Bl/6 mice, lpg2- >5 months after infection
in C57Bl/6 mice, and lpg2- 1 month after infection in BALB/c mice. For both plots, each
data point represents one mouse and the horizontal bars represents the mean for all mice.
P values were calculated by the Student’s t-test. A. The percentage of parasites within
CD11c+ cells. For CD11c, the elevated percentage of lpg2- parasites within CD11c+ cells
does not depend on the duration of the experiment (1 versus 5 months after infection),
and is also present in BALB/c mice. B. The percentage of parasites associated (either
within or adjacent to) an Arg1-expressing host cell. In terms of Arg1 association, lpg2within BALB/c mice more closely resembles WT persistent parasites in C57BL/6 mice
than it does lpg2- in C57BL/6 mice. Thus, the elevated association with Arg1 correlates
with vaccine failure. Horizontal bars represent the mean for all mice.
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Figure 9. Stem immunogen model of concomitant immunity. Top: acute-phase L. major
cell (green oval) within host cell (HC) replicates, with progeny parasites going on to
infect new host cells where they too will replicate. Middle: quiescent L. major cell resides
within macrophage or DC (HC). Some quiescent parasites re-enter cell cycle and begin to
replicate similarly to acute-phase parasites. While some of the progeny parasites
successfully infect new cells and maintain the infection, most are killed, resulting in
antigen presentation and maintenance of immunity. Bottom: cartoon of stem cell biology
in which a quiescent stem cell re-enters the cell cycle in response to some signal and
divides. Daughter cells can then either remain stem cells or can differentiate, depending
on a variety of signals. What cues signal quiescent L. major to re-enter the cell cycle or
how the fate of progeny parasites is determined is unknown, but alterations of the host’s
immune status would affect the proportions of progeny parasites destined for survival or
destruction.
Supplementary figure S1. Slow-growing L. major increase duration of G1 phase. A. Cell
density of parasites cultured in M199-based (grey) versus RPMI-based (black) media as a
function of time post inoculation. Parasites in M199 media double every 9.0 hours,
whereas parasites cultured in the RPMI-based media double every 29.6 hours. B. DNA
content of cells grown in M199 (grey) and RPMI (black) as assessed by propidium iodide
(PI) staining intensity. C. Percent of parasites in M199 (grey bars) or RPMI (black bars)
that are in G1, S, or M/G2 phase in the cell cycle (corresponding to M1, M2, and M3 in
panel B, respectively). Also shown is the percentage of parasites from each growth
condition that are BrdU+ 2 hr after the addition of BrdU to the culture media. For the
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BrdU experiment, error bars represent standard deviation, N = 3 coverslips; > 227
parasites scored per condition. *** represent p < 3X10-5 by the Student’s t-test.
Supplementary figure S2. Neither CD11c- (A) nor iNOS-expression (B) correlate with
the number of persistent parasites per infected host cell. The numbers within the bars
represent the number of infected cells scored for each category.
Supplementary figure S3. Positive controls for RELMα staining. A and B. Starch-elicited
peritoneal exudate cells were either cultured in media without cytokines (A) or cultured
in the presence of IL-4 and IL-13 (100 U ml-1) for 48 h (B) and then stained to detect
RELMα (green) or nuclei (blue). Cytokine treatment induced RELMα which was easily
visualized with anti-RELMα antisera. Scale bar equals 5µm. C. Representative image of
a footpad tissue section from a foot persistently-infected with WT stained to detect
parasite histones (green, no parasites visible in this field), RELMα (red) and F4/80 (blue).
Scale bar equals 5µm.
Table 1. Persistent L. major replicate comparably within iNOS+ and iNOS- host cells. The
percentage of both ‘clusters’ and BrdU-positive parasites within iNOS+ host cells is the
same as the percentage of total parasites within iNOS+ cells.
Table 2. Comparison of persistent WT and lpg2- parasites in footpad tissue. For the
summary statistics presented here, E = # of experiments, M = total # of mice, and P =
total # of parasites. A. N = 2E/7M/1003P. B. N = 3E/10M/616P. C. N = 3E/10M/712P.
D. N = 3E/10M/1004P. E. N = 3E/3M/346P. F. N = 3E/8M/2535P. G. N = 2E/9M/1105P.
H. N = 1E/2M/123P. I. N = 3E/5M/477P. J. N = 3E/10M/175 parasite clusters. K. N =
3E/10M/512 parasite clusters. L. N = 3E/10M/213 parasite clusters.
126

Figure 1

127

Figure 2

128

Figure 3

129

Figure 4

130

Figure 5

131

Figure 6

132

Figure 7

133

Figure 8

134

Figure 9

135

Supplementary figure S1

136

Supplementary figure S2

137

Supplementary figure S3

138

Table 1

139

Table 2

140

Chapter 4

Concomitant immunity induced by persistent Leishmania major does not preclude
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Abstract
Many microbes have evolved the ability to co-exist for long periods of time within other
species in the absence of overt pathology. For potential pathogens, evolutionary
biologists have proposed benefits to the microbe from ‘asymptomatic persistent
infections’, most commonly invoking increased likelihood of transmission by longerlived hosts. Typically asymptomatic persistent infections arise from strong containment
by the immune system, accompanied by protective immunity; such ‘vaccination’ in the
presence of a non-sterilizing immune response is termed premunition or concomitant
immunity. Here we consider another potential benefit of persistence and concomitant
immunity: the ‘exclusion’ of competing super-infecting strains, in a manner reminiscent
of that seen in lyosgenic bacteriophage in prokaryotes. To investigate this in the
protozoan parasite Leishmania major, which provides a superb model for the study of
asymptomatic persistence, we used isogenic lines of comparable virulence bearing
independent selectable markers. One was then used to infect genetically resistant mice,
yielding infections which healed and progressed to asymptomatic persistent infection;
these mice were then super-infected with the second marked line. As anticipated, superinfection yielded minimal pathology, showing that protective immunity had been
established. The relative abundance of the primary and super-infecting secondary
parasites was then assessed by plating on selective media. The data show clearly that
super-infecting parasites were able to colonize the immune host effectively, achieving
numbers comparable to and sometimes greater than that of the primary parasite. We
conclude that induction of protective immunity does not guarantee the Leishmania
parasite exclusive occupation of the infected host. This finding has important
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consequences to the maintenance and generation of parasite diversity in the natural
Leishmania infectious cycle alternating between mammalian and sand fly hosts.

144

Introduction
Persistent host/pathogen relationships are often characterized by a ‘stalemate’ in which
the host neither succumbs to disease nor is able to completely achieve sterile cure.
Persistent infections can show varying degrees of pathology, ranging from chronic overt
disease to asymptomatic infections (1-5). Especially for asymptomatic persistent
infections, a key component is a strong immune response on the part of the host, which is
required to keep pathogen numbers in check. In some cases, this immune response also
serves to protect against pathology resulting from subsequent re-infection by the same
pathogen, a process known as premunition or concomitant immunity (6-8).
Long-term host/pathogen relationships carry with them benefits and risks to both
partners, and have been the subject of a considerable study from an evolutionary
perspective (9-11). In the case of concomitant immunity, the host benefits by its immune
system’s ability to control the infection and minimize pathology, as well as protection
from disease arising from new infections. However, this comes at the cost of increased
risk of disease reactivation, typically arising from immunosuppression or stress (1, 4, 12).
From the pathogen’s perspective, while concomitant immunity decreases microbial
numbers, it may improve the likelihood of transmission due to the increased longevity of
the infected host.
A second potential benefit to the pathogen is ‘exclusivity’, in that concomitant immunity
may reduce the invasion of the host by other strains or species. In the case of
Schistosoma mansoni, concomitant immunity may limit intraspecific competition for
limited resources (6) (13). A further benefit of exclusivity is transmission, in
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guaranteeing transmission of the primary infecting line over that of secondary ‘invading’
pathogens. In some respects this scenario resembles that proposed for lysogenic
bacteriophages, which are generally resistant to super-infection with closely related
phage (14).
The protozoan parasite Leishmania major provides an excellent model for investigating
forces of concomitant immunity and persistence. L. major is transmitted to mammalian
hosts by the bite of phlebotomine sand flies, and in laboratory mice a range of pathology
ensues depending on both the particular parasite and mouse strain (15). Infections of
genetically susceptible mice (such as BALB/c) with most L. major strains yields a
progressive and fatal infection (15). In contrast, infection of genetically resistant mice
(e.g. C57BL/6) initially gives rise to a progressive parasitemia and lesion pathology at the
site of inoculation similar to that seen in BALB/c mice, but after 4-6 weeks an immune
response develops which controls both parasitemia and pathology (15, 16). Notably, the
healed mice are effectively vaccinated and resistant to disease pathology from subsequent
infections. Following healing, and for the remainder of the host’s life, a small number of
parasites persist in the skin at the site of inoculation and in the regional lymph node
draining that site (17). In keeping with concomitant immunity/premonition paradigm,
these persistent parasites appear to be important for the maintenance of an antiLeishmania immune response, as treatment resulting in sterile cure is associated with the
loss of immunity (18)(19).

The strong protective immunity induced by persistent

Leishmania is the basis for the ancient practice of leishmanization, in which live, virulent
parasites are intentionally inoculated in inconspicuous sites of the body to protect against
natural infection and pathology at other sites (20).
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Importantly the asymptomatic persistent Leishmania infections of C57BL/6 mice fit
several criteria relevant to understanding of the benefits and tradeoffs of concomitant
immunity. The animals are healthy, and despite the small numbers of persistent parasites
(< 1000 / mouse), they can be efficiently transmitted to sand flies (21-23). What has not
been solidly addressed previously in the literature is exclusivity; while it is well known
that the persistently infected mammalian host is vaccinated from disease pathology, it has
not been rigorously shown whether the long lived persistently infected host can be
successfully colonized by secondary parasite exposure. Several studies have evaluated
the potency of the immune response maintained by persistent parasites by injecting
parasites in a primary site, waiting for the lesion to resolve, and then injecting parasites
into a secondary site and determining the parasite load there (19, 24-26). The data from
these studies would seem to suggest that persistent parasites do not generate “exclusivity”
in that viable parasites were recovered from the site of secondary challenge. However,
the ability of L. major to traffic to sites distant from the site of inoculation (17) raised the
possibility that these parasites actually arose from the primary infection, perhaps
accentuated by the transient reactivation of parasites at the primary infection site reported
by Mendes et al (24).
To assess the question of exclusivity, we generated parasites derived from the same strain
of L. major of equal virulence but bearing independent drug resistance markers
(PHLEO/phleomycin and SAT/nourseothricin). This were then used in the classic
infection/challenge persistence model, using the SAT strain as the primary infection,
which gave rise to the expected lesion/healing/persistence phenomenon, followed by
injection with the PHLEO strain in the opposite foot. The results show clearly that under
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these conditions Leishmania persistence is not accompanied by ‘exclusivity’, in that
equivalent numbers of both ‘primary’ and ‘secondary’ parasites persisted at their
respective sites of inoculation. These data suggest that while persistent L. major
vaccinate its host from disease pathology, it does not confer exclusivity to the acquisition
of secondary infecting Leishmania. This finding has important consequences to the
maintenance and generation of Leishmania genetic diversity, including that arising
through sexual processes (27, 28).
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Materials and Methods
Parasite strains and culture
The generation of both the phleomycin resistant parasites (SSU:IR1PHLEO-YFP;
referred to here as LmjF PHLEO) and the nourseothricin-resistant parasites (SSU:SATTK-LUC; referred to here as LmjF LUC-SAT) used in this study was described
previously (29, 30). Parasites were grown at 26˚C in M199 medium (US Biologicals)
supplemented with 40 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid
(HEPES) pH 7.4, 50 μM adenosine, 1 μg ml−1 biotin, 5 μg ml−1 hemin, 2 μg ml−1
biopterin and 10% (v/v) heat-inactivated fetal calf serum {Kapler, 1990 #126}.
Nourseothricin (Jena Bioscience, Jena, Germany) was used at a concentration of 100
µg/ml and phleomycin (Sigma, St. Louis, MO) was used at a concentration of 20 µg/ml.
Infective metacyclic-stage parasites were recovered using the density gradient
centrifugation method (31).
Mouse infections
Animal studies were approved by the Animal Studies Committee at Washington
University (protocol #20090086) in accordance with the Office of Laboratory Animal
Welfare's guidelines and the Association for Assessment and Accreditation of Laboratory
Animal Care International.
Female C57Bl/6J mice (Jackson Labs) were injected subcutaneously in a hind footpad
with 105 metacyclic stage parasites. Naïve mice (6-8 weeks old) were injected in the left
hind footpad. Secondary injections took place in the right hind footpad at a time point >1
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month after primary lesions had resolved. Footpad lesion pathology was measured using
a Vernier caliper (Mitutoyo). Luciferase activity was determined as described elsewhere
(30). Briefly, mice were given a dose of D-luciferin (150 µg gram-1 body weight;
Biosynth) in PBS 10 minutes prior to imaging with an IVIS 100 imaging system
(Xenogen Corp). Limiting dilution assays were performed as described previously (32),
with the addition of phleomycin or nourseothricin as indicated.
Statistics
Data are presented as the arithmetic mean ± the standard deviation. P values were
calculated by the Student’s t-test.
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Results
Development of two genetically marked L. major with equivalent virulence in resistant
mice.
For this study, we used two L. major Friedlin V1 parasites expressing genes conferring
resistance to the antibiotics nourseothricin (SAT) or phleomycin (PHLEO). The
nourseothricin resistant parasites also express firefly luciferase, and will be referred to
hereafter as “LmjF-LUC-SAT”, while the phleomycin resistant parasites will be referred
to as LmjF-PHLEO. To confirm that the LmjF-LUC-SAT and LmjF-PHLEO parasites
were of comparable virulence in mice, 105 metacyclic-stage parasites were inoculated
into the footpads of naïve C57BL/6 mice (5 mice/group), and the lesion pathology was
monitored over time (Fig. 1A). Both lines exhibited disease progression typical of L.
major / C57BL/6 infections, with lesions developing between 10-17 days post infection
and reaching their maximum (~1.4 mm in thickness) around 30 days post infection.
Thereafter the lesions declined, and were completely resolved by 130 days post-infection
(Fig. 1A). At this time, mice were sacrificed and the parasite titers in the infected feet
were enumerated by limiting dilution analysis (Fig. 1B). No significant difference in the
number of persistent parasites was seen, with LmjF-LUC-SAT and Lmj-PHLEO showing
a similar range (Fig 1B) and mean (25and 32 parasites / foot; P > 0.45 by Student’s ttest). We judged these lines to be of comparable virulence and suitable for the following
tests.
Healed mice were protected against pathology from subsequent challenge
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Two experiments were performed in which naïve mice (4-5 mice per experiment) were
inoculated with 105 purified metacyclic-stage LmjF-LUC-SAT parasites in the left hind
footpad primary infection site. These mice formed lesions which spontaneously resolved
similar to that shown in Fig. 1A (data not shown). At a time point >1 month later, 105
metacyclic LmjF-PHLEO parasites were inoculated into the right hind footpad secondary
infection site. Footpad swelling of both the primary (L) and secondary (R) injection sites
were then measured over time. We also used in vivo imaging of luciferase activity to
visualize LmjF-LUC-SAT parasites, as a second probe of whether transient reactivation
of primary parasites occurred (24).
As expected in both experiments the mice showed good protection, as evidenced by a
reduction in lesion pathology at the secondary ‘challenge’ site. Although there was some
between-experiment variation, in both experiments the lesions generated by the
secondary LmjF-PHLEO parasites were significantly smaller and resolved more rapidly
than those in naïve mice, (Figure 2A). We saw no evidence of reactivation by the
“primary” LmjF-LUC-SATR parasite, as judged by either lesion measurement (Figure
2B) or in vivo imaging of parasite luciferase (Figure 2C). Interestingly, in expt. 1 we saw
a low level of LUC expression in the persistent infection; in other studies we have seen
this as well, although in general persistent parasite numbers are insufficient for reliable
imaging (Hickerson & Beverley unpublished).
Roughly equivalent numbers of both “primary” and “secondary” parasites persist
We then measured the occurrence of both the primary and secondary- infecting parasites,
in both infection sites, by limiting dilution assays at day 87 or 139 post-infection. Total

152

parasites were assessed by growth in the absence of drug, while LmjF-LUC-SAT was
estimated from growth in media containing nourseothricin and LmjF-PHLEO from
growth in phleomycin. The results from individual mice from both experiments as well as
the global averages are shown in Fig 3.
Parasites were recovered from all primary infection sites, ranging from 14 to 504
parasites/foot, with an average of 282 ± 158 parasites recovered per foot (N = 9).

These

parasites were exclusively the primary LmjF-LUC-SAT parasite, as they were unable to
grow in the presence of phleomycin. In one animal the SAT marker was apparently lost;
similar results have been reported in L. tarentolae and attributed to the genetic plasticity
of the ribosomal RNA locus where gene conversion has been postulated (33), and we
have seen this occasionally in other experiments in L. major.
Parasites were also recovered from the secondary infection site from 8 of the 9 mice,
ranging from 14 to 785 parasites/foot with an average of 119 ± 156 parasites per foot.
Importantly, nearly all of the parasites recovered from the secondary infection site were
the LmjF-PHLEO parasite inoculated there (99 ± 3%). In only one mouse (#2-5) could
colonization of the secondary site by ‘primary’ infection site LmjF-LUC-SAT parasites
be found at all, suggesting that metastasis of parasites from the primary to the secondary
sites is relatively infrequent. Importantly, the numbers of ‘primary’ infection site LmjFLUC-SAT parasites were not significantly different from that seen for the ‘secondary’
infection site LMjF-PHLEO parasites (P > 0.08, Student’s T-test). These data show that
despite ‘vaccination’ as defined by prevention of lesion pathology, the protective
immunity is not ‘sterilizing’ against secondary infections and does not preclude efficient
colonization of the infected mouse.
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Discussion
A number of factors have been proposed to contribute to the maintenance of pathogens
for long periods of time in the host, including an insufficient immune response and the
benefits accruing to the pathogen from residing within a longer-lived host thereby
increasing the likelihood of transmission (9, 11). In many cases this relationship has
progressed to the point where the pathogen infection is asymptomatic, thereby fulfilling
the evolutionary dictum that a ‘successful pathogen does not kill its host too quickly”.
Often this asymptomatic persistence is accompanied by protection from disease induced
by further infections of the same or related pathogens, a process termed concomitant
immunity (6). Such a relationship provides benefits to both the pathogen and the host
through increased longevity of the latter (albeit with some risk of reactivation), and
increased transmission of the former.
Leishmania provides an attractive system for the study of concomitant immunity (17, 18,
24, 34-36) and here we have used this to consider another potential benefit to the
pathogen, one of ‘exclusivity’. Exclusivity would favor transmission of the primary
infecting pathogen due to reduction in the ability of secondary infecting parasites to
establishing in a previously infected host. However, our data show clearly that despite
induction of a protective immune response able to mitigate disease pathology, secondary
Leishmania major infections are nonetheless able to establish themselves effectively in a
previously infected host. While this result may have been anticipated from prior studies
(19, 25), this is the first time this has been established rigorously for Leishmania using
genetically marked parasites able to distinguish primary from secondary infections.
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In our studies we used an inoculum consisting of 105 purified metacyclic parasites.
While most sand flies transmit less than 600 parasites to mice, a few transmit up to 105
(22). Thus, the dose used here is not an unrealistic one. In addition, other studies using
low-dose infections (challenging with 100 metacyclics) yielded results similar to ours in
that parasites were harvested from the site of secondary infection (19, 24-26). Similarly,
sand flies convey other factors including saliva and secreted parasite molecules such as
proteophosphoglycan, both of which typically act to facilitate primary infections (37-40)
but which can also engender various protective responses (41-42). Thus future studies
may address this phenomenon in the context of natural sand fly transmission and the
dissection of the relative roles of sand fly saliva and secreted Leishmania molecules such
as PPG.
In our study, the immunity generated by persistent parasites was not sterilizing and the
average number of “secondary” parasites was not significantly different from that of the
“primary” parasites (Fig. 3). Nonetheless, the average number of secondary LmjFPHLEO parasites was about 2-fold less than the primary LmjF-LUC-SAT parasites,
which is consistent with previous studies, such as those of Mendez et al (2004) (24)
where 10-fold fewer parasites were isolated from the secondary infection site. As noted
earlier, while these authors did not use genetically marked parasites, our studies show
that the dissemination of parasites from the primary to the secondary infecting foot is
relatively infrequent, being seen in only 1/9 infected mice (Fig. 3, mouse #2-5). Thus,
while secondary infecting parasites may be able to gain access to the previously infected
host, they may experience a quantitative disadvantage in terms of transmission, especially
as the efficiency of sand fly infection following feeding on a persistently infected host is
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already low (~10%) (21). Such a quantitative advantage could over evolutionary time
provide a strong positive selective force favoring concomitant immunity in addition to the
previously mentioned factor of host longevity.
Consequences of ‘nonexclusive’ parasitism to parasite diversity and vaccination
strategies.
The finding that the immunity induced by primary L. major infections protects against
pathology without being sterilizing also has implications for the generation and
maintenance of Leishmania diversity. In regions where Leishmania is endemic,
mammalian hosts are likely subjected to multiple independent infections (43, 44). Over
time, this may result in the host being persistently infected with several genetically
distinct parasite lines. Once established, mixed infections could then potentially be
passed to sand flies, which have recently been shown to be the site of parasite genetic
exchange experimentally (28). Since the frequency of sand flies bearing Leishmania in
natural populations is relatively low (often just a few per cent) (45-47), maintenance of
mixed populations in persistent infections may act to increase the frequency at which
sand flies acquire mixed infections, which thereafter undergo genetic exchange and
generate diversity. While genetic exchange occurs relatively infrequently on a per
Leishmania cell basis (<10-4; (28)), Leishmania populations in sand flies are sufficient to
yield hybrid parasites at high frequencies (25% or greater per fly; (28) Sacks & Beverley,
unpublished data). Thus, the lack of ‘exclusivity’ even in the presence of protection
against disease pathology may result in increased opportunities for genetic exchange and
the emergence of new disease phenotypes in nature.
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Our data also have some consequences to vaccination strategies. Currently the ‘healed’
mouse is considered a ‘gold standard’ for the maintenance of effective immunity against
disease pathology, and the generation of live-attenuated parasite lines that persist without
pathology while immunizing against virulent challenge has been a priority in vaccine
research (48, 49). Our data suggest that such an approach would likely allow virulent
parasites from subsequent natural infections to establish their own persistent infections
which would then pose a risk of reactivation. This may provide further impetus for the
development of vaccines conferring sterilizing, long-lasting protection against both
pathology and parasitemia.
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Figure legends

Figure 1. The LmjF-LUC-SAT and LmjF-PHLEO show comparable virulence in
infections of resistant mice. C57BL/6 mice (5 per group) were infected with 105
metacyclic stage LmjF-LUC-SAT or LmjF-PHLEO L. major. N = 1 experiment. A)
Measurements of lesion pathology (increase in footpad thickness). Error bars show the
standard deviation. B) Persistent parasites. 130 days post infection, mice were sacrificed
and the number of parasites persisting in the footpads was enumerated by limiting
dilution assay. Horizontal bars show the geometric mean.

Figure 2. Mice persistently infected with LmjF-LUC-SAT show protection from disease
pathology by secondary challenge with LmjF-PHLEO parasites. Mice (4-5/group) were
inoculated with 105 metacyclic LmjF-LUC-SAT parasites in the left hind footpad
(primary site), following which they developed lesions and then went on to heal (as
shown in Fig. 1A). At least one month after resolution of the primary lesions, each mouse
was inoculated in the right hind footpad (secondary site) with 105 metacyclic LmjFPHLEO parasites. In these experiments time 0 is when the secondary inoculation was
performed unless otherwise indicated. For all plots, error bars show the standard
deviation (n = 4 or 5 in expt. 1 or 2 respectively). A) Lesion pathology at the secondary
injection site. The dashed line represents the average of the data presented in Fig. 1A for
infections of naïve mice with LmjF LUC-SAT and LmjF-PHLEO for comparison. B)
Monitoring of reactivation of pathology at the site of primary infection (left foot). By
measuring total footpad thickness. C) Monitoring of reactivation of the primary LmjF165

LUC-SAT parasites at the primary (♦,■) or secondary (◊,□) infection sites site by
bioluminescent imaging of luciferase expression in vivo; experiment 1 (♦,◊); experiment
2 (■,□). The upper grey dashed line represents the level of luciferase activity normally
seen in C57BL/6 mice at peak parasitemia (~7 x 107 photons per second), and the lower
grey dashed line shows the background typical in these experiments (~5 x 103 photons
per second).

Figure 3. Retention of both primary and secondary infecting parasites following
secondary challenge despite protection from disease pathology. The graph plots the
number of persistent parasites present in sites of primary and secondary Leishmania
infections >10 weeks post secondary challenge as assessed by limiting dilution analysis
in unselective (white bar), nourseothricin-containing (gray bars; resistance mediated by
SAT marker) or phleomycin-containing (black bars; resistance mediated by PHLEO
marker) as described in the methods. The number of parasites in the primary infection
site (LmjF-LUC-SAT inocula) is displayed in the top graph, and the number of parasites
in secondary infection site (LmjF-PHLEO inocula) foot is displayed in the bottom graph.
The numbers between the two graphs represent the mouse identification number
(experiment number-mouse number). “Avg.” represents the mean for all mice.
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Chapter Five

Conclusions and future studies

This chapter was entirely written by Mike Mandell.
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Introduction
During the course of my thesis work, I sought to address three main questions. The first
question, as presented in chapter 2, was whether metacyclic-stage parasites differentiate
into the amastigote stage within dendritic cells and whether the promastigote-specific
virulence factor LPG is lost within these cells or retained for potential subsequent transfer
to macrophages. Chapters 3 and 4 focus on the life-long asymptomatic persistent
infections that occur following healing of lesion pathology. The focus of chapter 3 is
primarily to address whether or not persistent parasites replicate as well as to determine
their localization. In addition, I sought to determine if the attenuated lpg2- line resembled
wild type persistent parasites so as to be a model of parasite persistence that would
facilitate future studies by decreasing the lag time between mouse infections and
experiments. Finally, in chapter 3 I asked whether the immunity maintained by persistent
L. major is sufficiently strong to be sterilizing against super-infecting parasites, thus
gaining the persistent parasites exclusive ownership of and transmission from their host.
The main conclusions from these studies are presented here in the following three
sections. The remaining sections highlight a number of interesting questions raised by the
studies presented in this dissertation that should be the focus of future work. The first of
these involve testing aspects of the stem immunogen model of concomitant immunity that
was presented in chapter 3 and that will be discussed again below. In addition, two other
future aims are presented, both dealing with the capacity of lpg2- L. major to vaccinate
BALB/c, but not C57BL/6 mice, against virulent challenge (1, 2).
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The timing of amastigogenesis-related changes in L. major is variable, depending on the
host cell type infected, allowing for the retention of the LPG, a virulence factor critical to
parasite establishment in mice (chapter 2)
My studies showed that the timing of some developmental changes that are associated
with parasites differentiating from the infectious metacyclic stage to the intracellularly
replicating amastigote stage differs depending on the type of host cell that is infected. In
these studies, I infected peritoneal macrophages, bone marrow macrophages, and bone
marrow dendritic cells with metacyclic stage parasites and compared the sequence and
timing of parasite differentiation as assessed by six markers that are differentially
expressed between the two stages of the parasite life cycle. In general, the sequence of
amastigote marker induction was similar in all three cell types and amastigote-like
phenotypes for each marker individually were present on at least some parasites in all cell
types by 24 hours after infection. These data suggest that the parasites do not remain
metacyclics within the different cell types, including within dendritic cells which are one
of the first types of cells to be infected in vivo (3). In fact, amastigote marker induction
was similar in all three host cell types in terms of the down-regulation of paraflagellar rod
(PFR), the induction of two unidentified amastigote-specific antigens, and in the
induction of a YFP transgene which is down-regulated in amastigotes.
However, fewer parasites within the bone marrow derived cells re-entered the cell cycle
as assessed by BrdU incorporation and lost LPG expression as compared with the
reference peritoneal macrophages. By 48 hours post-infection, most parasites within
peritoneal macrophages were LPG-negative. In contrast, 37% or more of the parasites
within the bone marrow cells retained high-level LPG expression at 72 hours after
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infection. These data imply that the timing of differentiation as assessed by these markers
is somewhat plastic and dependent on the type of host cell infected. Alternatively, the
parasites within bone marrow derived cells may undergo an incomplete differentiation in
which relatively early developmental changes take place and then the parasites arrest
their development prior to cell cycle re-entry and LPG loss. Future work could focus on
what differences between the three host cell types result in the differences seen here.
These data are important for two reasons. First, they suggest that, under in vivo
conditions in which parasites appear to be transferred from the first cell types infected
(including dendritic cells) to macrophages by ~48 hours after infection, macrophages are
likely to encounter promastigote-specific virulence factors such as LPG which are
important in the establishment phase of infection. Second, the fact that parasite
differentiation can be slowed down or even arrested in vitro suggests that parasites may
also be able to do this in vivo, thus prolonging the duration in which LPG and potentially
other promastigote-specific virulence factors could interact with host cells to promote
parasite establishment. In addition to my data, one of the main contributions of my work
that is presented in chapter 2 is the evaluation of cytological markers of differentiation, as
such reagents are potentially useful to the field. Uses for these markers could include
identifying environmental signals that are either positive or negative regulators of
differentiation or as read-outs for genetic studies of amastigogenesis.
Studies of the replication and localization of persistent WT and lpg2- L. major in mice
(chapter 3)
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As the number of persistent parasites within a mouse remains roughly constant over time,
I asked whether persistent parasites were replicating or in a quiescent state. My studies
show that persistent parasites do indeed replicate. Continual parasite replication despite
constant parasite numbers strongly implies that persistent parasites must also undergo
destruction. Although persistent parasites do replicate, it appears that they do so less than
do acute-phase parasites. Further studies suggested that this difference in replication is
attributable to the presence of a slow or non-replicating sub-population of persistent
parasites which is not detected in the acute phase. As I was unable to find parasites within
persistently infected tissue that were obviously undergoing destruction, I assume that all
of the parasites which were visualized, including those that appear to be poorly
replicating, are alive. Further studies, which will be described later in this chapter, are
necessary to test this assumption in order to rule in our out the existence of a quiescent
sub-population. Until that time, I propose that persistent parasites can be classified into
three sub-groups: replicating persistent, quiescent persistent, and terminal persistent
(parasites that are destined for destruction).
An obvious question arising from the classification of persistent parasites into these three
groups (replicating, quiescent, and terminal) is whether the different classes of parasites
are found within different host cell types. The localization of persistent parasites has been
a somewhat controversial issue in the field, at least in part resulting from the “safe cell”
hypothesis that was proposed by Bogdan et al (2000) (4). This model assumes that
macrophages would be unfit host cells for persistent Leishmania owing to their ability to
express high levels of iNOS. Instead, Bogdan showed that some persistent parasites in
lymph nodes were within fibroblasts, which typically were iNOS-negative. These
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fibroblasts were proposed to be a crucial reservoir in which parasites could reside during
the persistent phase. Although no other study has been published that supports or refutes
the safe cell model, this study has been cited 87 times and the safe cell model has to some
extent become dogma. Contrary to Bogdan’s data, I found very few persistent parasites
within fibroblasts and instead found that the vast majority of persistent L. major to be
within macrophages and dendritic cells in both footpad and lymph node tissue. This
finding does not support the essentiality of fibroblasts as safe cells for persistent
Leishmania. In addition, although many of the infected host cells expressed iNOS, the
parasites within iNOS+ cells appeared to be viable and replicating, calling into question
the central assumption of the safe cell model that iNOS-expressing host cells cannot
support parasite survival. Therefore, my data do not support a safe cell model in which
persistent parasites “hide-out” from iNOS-expressing cells within fibroblasts.
Instead, my data suggest that persistent infections are likely quite dynamic systems
driven by constant parasite replication in which progeny parasites can have one of two
fates. Some parasites go on to infect a new macrophage or dendritic cell in which they
survive as either replicating or quiescent forms, thus maintaining the persistent infection.
Other progeny go on to face destruction in other macrophages or dendritic cells, which
keeps parasite numbers from increasing. I propose that antigens from those killed
parasites could be presented and may have a role in stimulating the immune system and
consequently maintaining protective immunity. If this is the case, the replicating
persistent parasites are crucial both for their own self-regeneration as well as constantly
providing a continual immune boost in the form of progeny parasites that are destined for
killing. In chapter 3, I compare this model with stem cells, in which a stem population
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replicates with some daughter cells remaining pluripotent and maintaining the stem cell
population while other daughter cells become terminally differentiated. As will be
discussed later in this chapter, future work should focus on testing whether or not parasite
killing is important for antigen presentation by infected cells.
Another aim of the work presented in chapter 3 was to compare the replication and
localization of attenuate lpg2- parasites, which previously have been proposed as a model
that would allow for more rapid establishment of persistent infections (5), with what is
seen with wild type persistent parasites. lpg2- parasites resembled persistent WT parasites
in terms of the percent of parasites labeling with BrdU, indicative of similar replication.
Furthermore, my analysis suggests that both quiescent and replicating sub-populations of
lpg2- exist in mice. Similar to wild type persistent parasites, lpg2- parasites are found
within macrophages and dendritic cells, many of which express high levels of iNOS
protein. However, I observed two differences in the nature of the host cells infected by
lpg2-: first that a higher percentage of lpg2- parasites were found in DCs, and second, in
that more lpg2- -infected host cells or a host cell directly adjacent to them expressed
arginase 1 (Arg1) that was seen with persistent WT parasites. Arg1 association correlated
inversely with the ability of lpg2- to vaccinate mice against virulent challenge, as the
association between lpg2- and Arg1 was seen in C57BL/6 mice which are not vaccinated
by lpg2-, but was not seen in BALB/c mice, which are strongly protected by lpg2- (1, 2).
Taken together my data supports the use of lpg2- as a model of WT persistence,
especially in the BALB/c mouse.
Do persistent parasites use their host’s protective immunity to exclude super-infecting
competitors? (Chapter 4)
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A number of potential benefits have been proposed for pathogens which immunize their
hosts. In chapter 4, I proposed another such benefit that persistent L. major might achieve
through protecting their hosts against subsequent infection: that of exclusivity. If the
immunity that is maintained by persistent parasites is sufficient to prevent the
establishment of super-infecting parasites, then the first parasite to infect a host would
gain a monopoly on that host, which from then on could only transmit the genome of the
first parasite to infect. The ability of a parasite to gain exclusivity would be highly
selective and would be predicted to move quickly through a population. Using genetically
marked parasites of equivalent virulence, I showed that persistent parasites do not gain
exclusivity, but rather that super-infecting parasites can become established and persist in
similar numbers within their host. These data suggest that, in nature, a host could
potentially be infected with parasites derived from multiple independent infections, with
the parasites potentially being genetically and phenotypically distinct from each other.
Such mixed infections could then be passed on to sand flies, which have been shown to
support sexual recombination of L. major (6).
Is there a quiescent sub-population of persistent parasites and, if so, do the quiescent
persistent parasites differ from replicating persistent parasites or acute-phase
amastigotes?
As discussed above, my data suggest that there are two populations of persistent
parasites, one that is actively replicating and one that appears to be replicating slowly if at
all. One interpretation of this is that the slow replicating population represents a group of
viable parasites that replicate slowly either because they are in sub-optimal conditions for
growth or because they have exited the cell cycle and are in some sort of arrest or stasis.
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Another interpretation is that these parasites do not undergo replication as assessed by
BrdU labeling because they are the parasites that are dead or dying, and were not
identified as such previously because the assays used in chapter 3 (TUNEL and
observation of morphological integrity) are simply the wrong assays of parasite
destruction. Thus, an important question is whether or not the parasites that are herein
referred to as quiescent persistent are actually alive. Perhaps the best approach to
demonstrate viability would be through some kind of metabolic labeling that would label
all living parasites but would not label host cells. One possible approach takes advantage
of a tunable protein expression system in which a reporter protein such as DsRed fused to
a destabilization domain (DD) can be stabilized in the presence of a small molecule that
can be administered to mice (7, 8). Mice could be infected with transgenic parasites
expressing DD-DsRed. Once the infections have entered the persistent phase, the mice
could be dosed with the small molecule Shield1, which would stabilize the DD and allow
for DsRed protein to accumulate within parasites that are actively undergoing
transcription and translation (in other words, alive). As discussed in chapter 3, the
quiescent parasites tended to be in host cells containing one to three parasites, and so the
absence of DsRed protein in parasites within such host cells relative to what is seen in
host cells containing four or more parasites would indicate that the parasites that I refer to
as quiescent are in fact dead. Alternatively, if DsRed-positivity of the parasites is
independent of the number of parasites per infected cells, this would argue the opposite.
If the quiescent persistent parasites are shown to be viable, the next question to be
addressed is whether or how they differ from replicating persistent parasites. Potentially,
quiescent persistent parasites differ from replicating persistent parasites only in terms of
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replication, possibly because the replicating persistent parasites are in an environment
more suitable to rapid replication. Alternatively, the quiescent persistent parasites may in
fact constitute a different stage of the parasite life cycle in a manner consistent with
quiescent Toxoplasma, herpes viruses, or Mycobacteria, all of which have gene
expression profiles that are specifically devoted to persistence (9-11). To address this
question, the gene expression profiles of quiescent persistent parasites (enriched in small
clusters) versus replicating persistent parasites (enriched in large clusters) could be
determined by microarray after RNA isolation by laser capture procedures. Additionally,
similar studies could be performed to compare the gene expression profile of persistent
parasites with that of acute-phase amastigotes. The purpose of these studies would be to
first, determine if Leishmania also has a stage of its life cycle that is specifically devoted
to persistence, and second, to identify markers that would distinguish persistent parasites
from acute-phase parasites or quiescent persistent parasite from replicating persistent
parasites.
Is parasite killing important for effective antigen presentation?
As has been mentioned elsewhere in this dissertation, persistent parasites have a role in
maintaining protective immunity (12, 13). Presumably, a key component of this role is
constant presentation of parasite antigens to the immune system. In the stem immunogen
model, I propose that some parasites become “terminally differentiated” (are killed) and
that the antigens that are presented are derived from these parasites rather than the
replicating “stem” Leishmania. It is reasonable to assume that host cells containing dead
Leishmania may more effectively present antigen than do host cells containing live
parasites, as live Leishmania have been shown to inhibit antigen presentation by their
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host cells (14-16). However, this assumption has not been proven and it is possible that
just as much antigen is presented by host cells containing healthy, replicating parasites as
is presented by host cells that contain antigens from parasites that they had previously
killed. Therefore, future studies should determine if intracellular parasite killing is a
prerequisite for effective antigen presentation and T cell stimulation as this question has
not been directly addressed in the literature. For these studies, macrophages or dendritic
cells could be infected with transgenic parasites expressing the model antigen OVA and
with thymidine kinase derived from herpes simplex virus. Some of the infected cells
could then be cultured in the presence of gangcyclovir, which should kill the parasites but
have minimal effects on the host cells. If host cells containing killed parasites more
efficiently present antigen, then OVA-specific OT-II T cells should proliferate more after
co-culture with the gangcyclovir-treated infected cells than after co-culture with the
untreated infected cells.
What is the role of host arginase 1 in vaccine failure of lpg2- -infected C57BL/6 mice?
When lpg2- -infected BALB/c mice are ‘challenged’ with virulent parasites, they are able
to prevent the virulent parasites from replicating to high titers and are protected from
disease pathology (1). However, lpg2- parasites are not sufficient to confer such
resistance to C57BL/6 mice unless the parasites are co-injected with CpG DNA as an
adjuvant (2). Data presented in chapter 3 demonstrates that association of parasites with
host arginase 1-expressing cells was a negative correlate of immunity to pathology. In
other words, a higher percentage of parasites in (C57BL/6 harboring lpg2-) which were
shown to be poorly protected in other studies, were either within or adjacent to an Arg1expressing host cell than were parasites within strongly protected C57BL/6 mice
180

harboring WT persistent parasites or BALB/c mice harboring lpg2- parasites (Table 5-1).
While this correlation does not prove that Arg1 expression results in vaccine failure, there
is ample evidence in the literature that suggests such a causal relationship is plausible
(17-24).
Like all arginases, Arg1 catalyzes the hydrolysis of L-arginine resulting in the production
of urea and L-ornithine, which is the precursor for polyamine synthesis (25). Cells
expressing high levels of Arg1 have been shown to quickly deplete L-arginine from
culture media and are thought to also have the capacity to deplete arginine in their microenvironment in vivo (26). L-arginine depletion has been shown to diminish effector T-cell
function by decreasing the number of T-cell receptors present on the cell surface and by
preventing T-cell proliferation in response to antigen stimulation (23, 26, 27). These
results have been confirmed in L. major-specific T-cells, which were also shown to
express lower amounts of interferon-γ upon antigen stimulation under conditions of
arginine-deprivation (24). In addition, depletion of essential amino acids including
arginine is reported to induce naïve T-cells to adopt a regulatory phenotype (20). As
adoptive transfer of Leishmania-specific Treg cells leads to reactivation of persistent L.
major infections (28), an increase in these cells would also likely be disease-promoting in
the event of virulent L. major challenge. Arginine depletion may also have a role in
preventing the generation of nitric oxide (NO), an effector molecule required for the
control of L. major infection in vitro and in vivo (29-31). NO is generated through the
enzymatic activity of iNOS, which uses L-arginine as a substrate (27). Numerous studies
demonstrate that reduction in arginine availability results in corresponding reductions in
NO output by iNOS-expressing cells (27, 32-35). In addition to these effects of arginine
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depletion in iNOS activity, arginine depletion has also been demonstrated to have effects
on NO production by decreasing iNOS expression (22).
Another consequence of elevated levels of Arg1 expression in association with lpg2parasites could be an increase in the amounts of polyamines which appear to be limiting
for L. major early in mouse infection, thus facilitating parasite growth (27, 34, 36). In
addition to being potentially beneficial to the parasite in terms of nutrition, polyamines
have also been shown to attenuate iNOS expression and function (17-19).
Some of the mechanisms mentioned above by which Arg1 expression could result in
vaccine failure by lpg2- (e.g. effects on NO production or providing polyamines to
“challenge” parasites) act directly upon the parasite’s environment and thus depend on
the up-regulation of Arg1 in or the recruitment of Arg1-expressing cells to the challenge
site, a point which has not yet been established. Other mechanisms, such as those
involving T-cells, act indirectly on the parasite’s environment and would not require
close association between parasite-infected cells at the challenge site and Arg1+ cells.
Future work should aim to increase the size of the data-set demonstrating a correlation
between Arg1-association and vaccine failure. While my data suggests such a correlation
exists, more data points are needed to firmly conclude this point. To this end,
experiments could be performed to determine the level of Arg1 association with lpg2- in
C57BL/6 mice that have been treated with CpG DNA as an adjuvant and that are strongly
protected against pathology from new infections. In addition to lpg2-, several other L.
major lines exist which persist indefinitely without causing pathology (e.g. fbp- or iscl-),
but studies regarding their ability to vaccinate different strains of mice has not been
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published (37, 38). Studies could be performed with these parasite lines to determine
their vaccination status in different mouse strains and the level of Arg1 association. If
after these studies the correlation between Arg1 association and vaccine failure is still
apparent, future work should focus on determining if Arg1 association is causative of
vaccine failure as outlined below.
To determine if the observed Arg1-association causes vaccine failure, the ability of lpg2parasites to vaccinate Arg1-deficient mice and their WT litter-mates of the appropriate
mouse strain (C57BL/7) could be assessed. Fortunately, such mice have been generated:
Arg1 has been deleted from most macrophages and neutrophils in Arg1 flox/flox; LysMcre
mice (39). If Arg1 is responsible for vaccine failure in C57BL/6 mice, then arginasedeficient Arg1 flox/flox; LysMcre mice should be protected from virulent challenge by prior
lpg2- infection while their wild type siblings would remain susceptible.
If Arg1 expression is found to be responsible for vaccine failure, future work should
focus on understanding the mechanism by which this occurs. As mentioned above, the
“direct” effects of Arg1 depend on its localization at the challenge site. Thus, if Arg1
results in vaccine failure by attenuating NO production or increasing the amount of
polyamines available to the parasites, then the expression of Arg1 within the challenge
site of lpg2- -infected C57BL/6 mice should be greater than that of “immune” lpg2- infected BALB/c mice. If this is the case, future studies could focus on potential
differences between “immune” and non-imnune” lpg2- -infected mice in terms of iNOS
expression and NO production at the challenge site.
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If lpg2- vaccinates Arg1 conditional knock-out mice but not their WT litter-mates, then
this system will allow for a good way to determine if Arg1 affects T-cell function by the
use of adoptive transfer experiments of T-cells from lpg2- -infected Arg1 flox/flox; LysMcre
mice and WT Arg1 flox/flox mice into naïve mice followed by virulent L. major challenge.
As previous studies have demonstrated that such transfers of T-cells from immune mice
confer protection to naïve mice (40), the T-cells from the “immune” Arg1 flox/flox;
LysMcre mice would be expected to be protective. If Arg1-induced vaccine failure results
from altered T-cell phenotypes and not from the “direct” effects described above, then
adoptive transfer of T-cells from lpg2- -infected Arg1 flox/flox would not be expected to
confer protective immunity. If this is indeed the result, then modifications of this
adoptive transfer system could be made to further define how Arg1 affects T-cells
resulting in vaccine failure.
Use of lpg2- vaccination model to identify anti-Leishmania effectors in addition to NO
As mentioned above, nitric oxide is clearly important in controlling L. major infections in
vitro and in vivo (29-31). As such, cells expressing iNOS have been considered likely
sites of parasite destruction (4, 41-43). However, in Chapter 3 I present data showing that
both lpg2- and WT persistent parasites were capable of surviving and replicating within
host cells expressing high levels of iNOS. This surprising result raises the possibility that
while NO is necessary for Leishmania killing, it may not be sufficient and other effector
molecules in addition to NO are also required.
As described above and in table 5-1, infection of C57Bl/6 mice with lpg2- parasites does
not lead to protective immunity against subsequent virulent challenge while lpg2-
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infection of BALB/c mice does confer protection. Thus, it is reasonable to assume that
the host cells containing L. major at the challenge site in “immune” mice (lpg2- //
BALB/c) differ in some way relevant to Leishmania killing from L. major-containing
cells in “non-immune” mice (lpg2- // C57BL6). One possible difference is in terms of
iNOS expression. However, my data show that ~70% of lpg2- parasites are within iNOS+
host cells in either BALB/c (“immune”) or C57BL/6 (“non-immune”) mice. If the
phenotype of infected cells at the challenge site resembles that of cells at the site of
primary lpg2- infection, then the levels of iNOS expression by cells at the challenge site
may not differ with vaccination status. Differences in the ability of Leishmaniacontaining cells to kill parasites in “immune” versus “non-immune” mice despite similar
levels of iNOS expression and NO generation would imply that other factors are also
involved. As such, a global comparison of the infected host cells at the challenge site
between “immune” and “non-immune” mice may present a good system to identify these
factors.
Some of the differences between the Leishmania containing cells in “immune” versus
“non-immune” mice could be in terms of the activity of constitutively-expressed proteins
which are normally in an inactive form but are activated under conditions of infection by
post-translational modification. Alternatively, the relative expression of genes involved in
Leishmania killing may differ between Leishmania-containing cells in “immune” mice
versus those in “non-immune” mice. I propose to use a microarray-based approach to
focus on the latter class of factors. For these studies, I will use C57BL/6 that have been
simultaneously injected with lpg2- parasites and with CpG DNA as an adjuvant and
which are strongly protected against virulent challenge (2) as the “immune” mice, thus
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eliminating mouse strain as a potentially confounding variable in comparisons with “nonimmune” lpg2- -infected mice of the same strain.
Several control experiments must be performed prior to trying to obtain RNA from
infected cells. First, it will be important to establish the appropriate time frame at which
parasite killing is occurring in “immune” mice but not in “non-immune” mice. It will also
be important to eliminate the possibility that the difference in the ability of “immune”
versus “non-immune” mice to kill L. major results merely from the relative inability of
“non-immune” mice to generate NO at the challenge site. If the “immune” and “nonimmune” lpg2- -infected mice generate comparable levels of NO following virulent
challenge, then experiments can proceed.
RNA from infected host cells of both “immune” and “non-immune” mice would then be
harvested by laser-capture procedures at the earliest time-point at which parasite killing is
seen in “immune” mice, and differences in gene expression would be detected by
microarray. While such an approach would miss those proteins whose anti-Leishmania
activity is affected by post-translational modification, it may identify novel anti-microbial
pathways that may also be important for the control other intracellular pathogens in
addition to Leishmania.

186

References
1.

Uzonna, J.E., G.F. Spath, S.M. Beverley, and P. Scott. 2004. Vaccination with
phosphoglycan-deficient Leishmania major protects highly susceptible mice from
virulent challenge without inducing a strong Th1 response. J Immunol 172:37933797.

2.

Kebaier, C., J.E. Uzonna, S.M. Beverley, and P. Scott. 2006. Immunization with
persistent attenuated Delta lpg2 Leishmania major parasites requires adjuvant to
provide protective immunity in C57BL/6 mice. Infect Immun 74:777-780.

3.

Ng, L.G., A. Hsu, M.A. Mandell, B. Roediger, C. Hoeller, P. Mrass, A.
Iparraguirre, L.L. Cavanagh, J.A. Triccas, S.M. Beverley, P. Scott, and W.
Weninger. 2008. Migratory dermal dendritic cells act as rapid sensors of
protozoan parasites. PLoS Pathog 4:e1000222.

4.

Bogdan, C., N. Donhauser, R. Doring, M. Rollinghoff, A. Diefenbach, and M.G.
Rittig. 2000. Fibroblasts as host cells in latent leishmaniosis. J Exp Med
191:2121-2130.

5.

Spath, G.F., L.F. Lye, H. Segawa, D.L. Sacks, S.J. Turco, and S.M. Beverley.
2003. Persistence without pathology in phosphoglycan-deficient Leishmania
major. Science 301:1241-1243.

6.

Akopyants, N.S., N. Kimblin, N. Secundino, R. Patrick, N. Peters, P. Lawyer,
D.E. Dobson, S.M. Beverley, and D.L. Sacks. 2009. Demonstration of genetic
exchange during cyclical development of Leishmania in the sand fly vector.
Science 324:265-268.

187

7.

Banaszynski, L.A., L.C. Chen, L.A. Maynard-Smith, A.G. Ooi, and T.J.
Wandless. 2006. A rapid, reversible, and tunable method to regulate protein
function in living cells using synthetic small molecules. Cell 126:995-1004.

8.

Madeira da Silva, L., K.L. Owens, S.M. Murta, and S.M. Beverley. 2009.
Regulated expression of the Leishmania major surface virulence factor
lipophosphoglycan using conditionally destabilized fusion proteins. Proc Natl
Acad Sci U S A 106:7583-7588.

9.

Cleary, M.D., U. Singh, I.J. Blader, J.L. Brewer, and J.C. Boothroyd. 2002.
Toxoplasma gondii asexual development: identification of developmentally
regulated genes and distinct patterns of gene expression. Eukaryot Cell 1:329-340.

10.

Betts, J.C., P.T. Lukey, L.C. Robb, R.A. McAdam, and K. Duncan. 2002.
Evaluation of a nutrient starvation model of Mycobacterium tuberculosis
persistence by gene and protein expression profiling. Mol Microbiol 43:717-731.

11.

Efstathiou, S., and C.M. Preston. 2005. Towards an understanding of the
molecular basis of herpes simplex virus latency. Virus Res 111:108-119.

12.

Belkaid, Y., C.A. Piccirillo, S. Mendez, E.M. Shevach, and D.L. Sacks. 2002.
CD4+CD25+ regulatory T cells control Leishmania major persistence and
immunity. Nature 420:502-507.

13.

Tabbara, K.S., N.C. Peters, F. Afrin, S. Mendez, S. Bertholet, Y. Belkaid, and
D.L. Sacks. 2005. Conditions influencing the efficacy of vaccination with live
organisms against Leishmania major infection. Infect Immun 73:4714-4722.

14.

Courret, N., E. Prina, E. Mougneau, E.M. Saraiva, D.L. Sacks, N. Glaichenhaus,
and J.C. Antoine. 1999. Presentation of the Leishmania antigen LACK by

188

infected macrophages is dependent upon the virulence of the phagocytosed
parasites. Eur J Immunol 29:762-773.
15.

Fruth, U., N. Solioz, and J.A. Louis. 1993. Leishmania major interferes with
antigen presentation by infected macrophages. J Immunol 150:1857-1864.

16.

Reiner, N.E., W. Ng, T. Ma, and W.R. McMaster. 1988. Kinetics of gamma
interferon binding and induction of major histocompatibility complex class II
mRNA in Leishmania-infected macrophages. Proc Natl Acad Sci U S A 85:43304334.

17.

Bronte, V., and P. Zanovello. 2005. Regulation of immune responses by Larginine metabolism. Nat Rev Immunol 5:641-654.

18.

Bussiere, F.I., R. Chaturvedi, Y. Cheng, A.P. Gobert, M. Asim, D.R. Blumberg,
H. Xu, P.Y. Kim, A. Hacker, R.A. Casero, Jr., and K.T. Wilson. 2005. Spermine
causes loss of innate immune response to Helicobacter pylori by inhibition of
inducible nitric-oxide synthase translation. J Biol Chem 280:2409-2412.

19.

Chaturvedi, R., M. Asim, S. Hoge, N.D. Lewis, K. Singh, D.P. Barry, T. de
Sablet, M.B. Piazuelo, A.R. Sarvaria, Y. Cheng, E.I. Closs, R.A. Casero, Jr., A.P.
Gobert, and K.T. Wilson. 2010. Polyamines Impair Immunity to Helicobacter
pylori by Inhibiting L-Arginine Uptake Required for Nitric Oxide Production.
Gastroenterology 139:1686-1698, 1698 e1681-1686.

20.

Cobbold, S.P., E. Adams, C.A. Farquhar, K.F. Nolan, D. Howie, K.O. Lui, P.J.
Fairchild, A.L. Mellor, D. Ron, and H. Waldmann. 2009. Infectious tolerance via
the consumption of essential amino acids and mTOR signaling. Proc Natl Acad
Sci U S A 106:12055-12060.

189

21.

El Kasmi, K.C., J.E. Qualls, J.T. Pesce, A.M. Smith, R.W. Thompson, M. HenaoTamayo, R.J. Basaraba, T. Konig, U. Schleicher, M.S. Koo, G. Kaplan, K.A.
Fitzgerald, E.I. Tuomanen, I.M. Orme, T.D. Kanneganti, C. Bogdan, T.A. Wynn,
and P.J. Murray. 2008. Toll-like receptor-induced arginase 1 in macrophages
thwarts effective immunity against intracellular pathogens. Nat Immunol 9:13991406.

22.

El-Gayar, S., H. Thuring-Nahler, J. Pfeilschifter, M. Rollinghoff, and C. Bogdan.
2003. Translational control of inducible nitric oxide synthase by IL-13 and
arginine availability in inflammatory macrophages. J Immunol 171:4561-4568.

23.

Gabrilovich, D.I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as
regulators of the immune system. Nat Rev Immunol 9:162-174.

24.

Munder, M., B.S. Choi, M. Rogers, and P. Kropf. 2009. L-arginine deprivation
impairs Leishmania major-specific T-cell responses. Eur J Immunol 39:21612172.

25.

Morris, S.M., Jr. 2007. Arginine metabolism: boundaries of our knowledge. J
Nutr 137:1602S-1609S.

26.

Makarenkova, V.P., V. Bansal, B.M. Matta, L.A. Perez, and J.B. Ochoa. 2006.
CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic
stress. J Immunol 176:2085-2094.

27.

Popovic, P.J., H.J. Zeh, 3rd, and J.B. Ochoa. 2007. Arginine and immunity. J Nutr
137:1681S-1686S.

190

28.

Mendez, S., S.K. Reckling, C.A. Piccirillo, D. Sacks, and Y. Belkaid. 2004. Role
for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis
and control of concomitant immunity. J Exp Med 200:201-210.

29.

Evans, T.G., L. Thai, D.L. Granger, and J.B. Hibbs, Jr. 1993. Effect of in vivo
inhibition of nitric oxide production in murine leishmaniasis. J Immunol 151:907915.

30.

Liew, F.Y., S. Millott, C. Parkinson, R.M. Palmer, and S. Moncada. 1990.
Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide
from L-arginine. J Immunol 144:4794-4797.

31.

Wei, X.Q., I.G. Charles, A. Smith, J. Ure, G.J. Feng, F.P. Huang, D. Xu, W.
Muller, S. Moncada, and F.Y. Liew. 1995. Altered immune responses in mice
lacking inducible nitric oxide synthase. Nature 375:408-411.

32.

Green, S.J., M.S. Meltzer, J.B. Hibbs, Jr., and C.A. Nacy. 1990. Activated
macrophages destroy intracellular Leishmania major amastigotes by an Larginine-dependent killing mechanism. J Immunol 144:278-283.

33.

Johann, A.M., V. Barra, A.M. Kuhn, A. Weigert, A. von Knethen, and B. Brune.
2007. Apoptotic cells induce arginase II in macrophages, thereby attenuating NO
production. Faseb J 21:2704-2712.

34.

Kropf, P., J.M. Fuentes, E. Fahnrich, L. Arpa, S. Herath, V. Weber, G. Soler, A.
Celada, M. Modolell, and I. Muller. 2005. Arginase and polyamine synthesis are
key factors in the regulation of experimental leishmaniasis in vivo. Faseb J
19:1000-1002.

191

35.

Munder, M., K. Eichmann, and M. Modolell. 1998. Alternative metabolic states
in murine macrophages reflected by the nitric oxide synthase/arginase balance:
competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J
Immunol 160:5347-5354.

36.

Iniesta, V., L.C. Gomez-Nieto, and I. Corraliza. 2001. The inhibition of arginase
by N(omega)-hydroxy-l-arginine controls the growth of Leishmania inside
macrophages. J Exp Med 193:777-784.

37.

Zhang, O., M.C. Wilson, W. Xu, F.F. Hsu, J. Turk, F.M. Kuhlmann, Y. Wang, L.
Soong, P. Key, S.M. Beverley, and K. Zhang. 2009. Degradation of host
sphingomyelin is essential for Leishmania virulence. PLoS Pathog 5:e1000692.

38.

Naderer, T., M.A. Ellis, M.F. Sernee, D.P. De Souza, J. Curtis, E. Handman, and
M.J. McConville. 2006. Virulence of Leishmania major in macrophages and mice
requires the gluconeogenic enzyme fructose-1,6-bisphosphatase. Proc Natl Acad
Sci U S A 103:5502-5507.

39.

Pesce, J.T., T.R. Ramalingam, M.M. Mentink-Kane, M.S. Wilson, K.C. El Kasmi,
A.M. Smith, R.W. Thompson, A.W. Cheever, P.J. Murray, and T.A. Wynn. 2009.
Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation
and fibrosis. PLoS Pathog 5:e1000371.

40.

Zaph, C., J. Uzonna, S.M. Beverley, and P. Scott. 2004. Central memory T cells
mediate long-term immunity to Leishmania major in the absence of persistent
parasites. Nat Med 10:1104-1110.

192

41.

Stenger, S., N. Donhauser, H. Thuring, M. Rollinghoff, and C. Bogdan. 1996.
Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide
synthase. J Exp Med 183:1501-1514.

42.

Stenger, S., H. Thuring, M. Rollinghoff, and C. Bogdan. 1994. Tissue expression
of inducible nitric oxide synthase is closely associated with resistance to
Leishmania major. J Exp Med 180:783-793.

43.

Serbina, N.V., T.P. Salazar-Mather, C.A. Biron, W.A. Kuziel, and E.G. Pamer.
2003. TNF/iNOS-producing dendritic cells mediate innate immune defense
against bacterial infection. Immunity 19:59-70.

193

Table 5-1

194

Appendix I

Localization studies of the amastigote-specific antigens recognized by mAB T17 and
mAB T18

Michael A. Mandell, Wandy L. Beatty, and Stephen M. Beverley1

1

Department of Molecular Microbiology, Washington University School of Medicine, St.

Louis MO 63110 USA

195

Author contributions
M.A.M performed experiments and wrote the text.
W.L.B performed experiments.
S.M.B. made comments on the text.

196

Introduction
One approach for identifying novel Leishmania factors involved in mammalian virulence
is by the identification of molecules that are specifically expressed by the amastigote
stage of the parasite’s life cycle, as such molecules are unlikely to have roles in cellular
“house keeping” or in sand fly virulence. Additionally, molecules with amastigotespecific expression are good candidates for reverse genetic studies, as their synthesis is
unlikely to be essential to promastigote-stage parasites, which is the stage of the parasite
life cycle most easily cultured in a laboratory setting and in which transfection
experiments are typically performed (1). More than two decades ago, Charles Jaffe
developed monoclonal antibodies that specifically recognize Leishmania major
amastigotes, but neither the molecules recognized by these antisera, nor their functions,
have been determined (2). In Chapter 2 of this thesis, I developed the use of two of these
antisera, referred to as T17 and T18, as “amastigote markers”. In that work, we showed
by immunofluorescence microscopy that the two amastigote-specific antisera had
different sub-cellular localization patterns, and hence recognized different antigens. We
also found that the T17 and T18 reactive molecules are induced by 8 hours after infection
of host cells, ultimately labeling >90% of the parasites by 11 hours post-infection. In this
work, we further describe the sub-cellular localization of the molecules recognized by
these two antisera by immunoflourescence and immunoelectron microscopy and identify
conditions that result in high level expression of the T17 and T18 antigens in by >40% of
parasites axenic culture for proteomic analysis.
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Materials and Methods
Parasite culture
L. major Friedlin V1 strain (MHOM/IL/80/Friedlin) parasites expressing YFP (yellow
fluorescent protein; SSU:IR1PHLEO-YFP) were generated as described elsewhere (3).
These parasites were grown at 26˚C in M199 medium (US Biologicals) supplemented
with 40 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES) pH 7.4,
50 μM adenosine, 1 μg ml−1 biotin, 5 μg ml−1 hemin, 2 μg ml−1 biopterin and 10% (v/v)
heat-inactivated fetal calf serum (1). For experiments in which amastigote marker
induction was assayed in the absence of host cells, 10 ml of parasites that had been in
stationary-phase for two days (2X108 cells) were pelleted and resuspended in 30 ml prewarmed RPMI 1640 (Invitrogen) and kept in a 37˚C for 24 hours with 5% CO2.
Macrophage infections
Peritoneal macrophages (PEMs) were elicited by a peritoneal injection of potato starch
into female C57Bl/6J mice (6-10 weeks old; Jackson Labs) harvested as described, plated
on glass coverslips, and maintained in DMEM (Invitrogen) containing 10% FCS and 2
mM L-glutamine in a 37˚C incubator with 5% CO2 (4). The day after the PEM
isolations, infective metacyclic-stage parasites were recovered using the density gradient
centrifugation method (5) and opsonized with serum from C5-deficient mice prior to
being added at a parasite to PEM ratio of 5:1. Extracellular parasites were removed 2
hours after infection by extensive washing. Infected PEMs were provided with fresh
media daily, and samples were prepared for microscopy 3 days after infection.
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Antibodies, immunofluorescence staining and microscopy
T17 and T18 antisera were provided by C. Jaffe as lyophilized mouse ascites fluid. For
these studies we used T17 that was prepared 1/7/1996 and T18 that was prepared
2/8/1991.
Samples of infected PEMs on coverslips were fixed in 4% (w/v) paraformaldehyde (PFA)
in phosphate-buffered saline (PBS) for 10 minutes. In vitro “differentiated” parasites
were were fixed in 4% (w/v) PFA in phosphate-buffered saline (PBS) for 2 minutes, and
then the parasite/PFA suspension was diluted 10-fold in PBS. Samples were washed in
PBS, and then blocked and permeabolized in PBS containing 5% (v/v) normal goat sera
(Vector labs) and 0.1% (v/v) Triton-X-100 for 30 min (blocking buffer). Parasite nuclei
were then stained with a pool of rabbit antibodies raised against L. major histones H2A,
H2Avariant, H2B, H3, and H4 (pooled at a ratio of 3:2:3:3:1 by titer) and used at a dilution of
1:750 in blocking buffer (Wong and Beverley, in preparation). T17 or T18 antibodies
were diluted 1:400 in blocking buffer. After a one hour incubation in primary antibodies,
unbound antibody was washed off in PBS and primary antibodies were detected with
Alexafluor488 goat anti-mouse and Alexafluor555 goat anti-rabbit (Invitrogen, both used
at a concentration of 2 μg ml−1). DNA was detected with Hoechst 33342 (Invitrogen,
used at a concentration of 5 μg ml−1) for wide-field microscopy or TOPRO-3 (Invitrogen,
used at a concentration of 2 μM) for confocal microscopy. After a 40 minute incubation,
samples were washed with PBS and mounted in ProLong Gold (Invitrogen).
In vitro “differentiated” parasites were were fixed in 4% (w/v) PFA in phosphatebuffered saline (PBS) for 2 minutes, and then the parasite/PFA suspension was diluted
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10-fold in PBS. Fixed parasites were then spun down and resuspended in PBS at a
concentration of 8 X 106 parasites per milliliter. Parasites (4 X 106) were then adhered to
glass cover slips by centrifugation. Blocking, permeabilization, and antibody staining was
then performed as described above.
Microscopy was performed on an Olympus AX-70 wide-field fluorescence microscope or
a Zeiss 510 META confocal laser scanning microscope. Cutoffs for saturation and
background levels were adjusted with Photoshop software (Adobe).
Immuno-electron microscopy
These studies were performed by Wandy Beatty in the Microbiology imaging facility.
For immunolocalization by transmission electron microscopy, infected cells were fixed in
4% paraformaldehyde/0.05% glutaraldehyde (Polysciences Inc., Warrington, PA) in
100mM PIPES/0.5mM MgCl2, pH 7.2 for 1 hr at 4˚C. Samples were infiltrated
overnight in the cryoprotectant 2.3M sucrose/20% polyvinyl pyrrolidone in
PIPES/MgCl2 at 4˚C. To permeabilize cells for antibody labeling samples were plungefrozen in liquid nitrogen and subsequently thawed in PBS at room temperature. This
technique was confirmed to permeabilize the host cell membrane and intracellular
organelle membranes. Samples were probed with the primary antibodies at 1:250
dilutions followed by FluoroNanogold anti-mouse Fab (1:250; Nanoprobes, Yaphank,
NY) and silver enhancement (Nanoprobes HQ silver enhancement kit). Samples were
washed in phosphate buffer and post-fixed in 1% osmium tetroxide (Polysciences Inc.,
Warrington, PA) for 1 hr. Samples were then rinsed extensively in dH20 prior to en bloc
staining with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for 1 hr.
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Following several rinses in dH20, samples were dehydrated in a graded series of ethanol
and embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 95 nm were cut with a
Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained
with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX transmission
electron microscope (JEOL USA Inc., Peabody, MA). All pre-labeling experiments were
conducted in parallel with omission of the primary antibody. These controls were
consistently negative at the concentration of Nanoprobes-conjugated secondary
antibodies used in these studies.
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Results and discussion
T17 epitope localizes to the amastigote flagella and surface and is also found in vesicles
within the host cell cytoplasm
To determine the localization of the antigen recognized by mAB T17, we stained PEMs
that had been infected for 72 hours with mAB T17, as well as antisera raised against L.
major histone proteins to localize parasite nuclei, and with Hoechst 33342 to detect DNA
(Figure 1A). The most intense T17 reactivity presented as a line at the parasites anterior
end proceeding outward from the kinetoplast to the anterior pole of the cell. This staining
pattern is consistent with mAB T17 recognizing the amastigote flagella, the length of
which is almost entirely within the flagellar pocket (6). Less intense staining was also
seen on the surface of amastigotes. This staining pattern was apparent on 91% of T17+
parasites scored (N = 222 parasites). As shown in Figure 1B and C, this localization
pattern was also found by immuno-electron microscopy.
Interestingly, mAB T17 reactivity was not limited to the parasite itself, but was also
showed a punctate staining pattern within the cytoplasm of infected, but not uninfected,
macrophages (Figure 2A). Immuno-electron microscopy images revealed that, in many
cases, the T17 antigen was concentrated just outside the phagolysosomal membrane at
the distal tip of the amastigote flagellum (Figure 2B) and was also found within
membranous compartments further away from the parasite-containing phagolysosome
(Figure 2C).
In summary, these results suggest that the mAB T17 antigen localizes predominantly to
the amastigote flagellum, and is somehow translocated to the parasite’s surface and out of
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the phagolysosome. These data are provocative when considered in the context of two
recent studies from other laboratories. First, Reiner’s laboratory has suggested that a
number of Leishmania proteins are delivered to the host cell within ‘exosomes’, which
could modulate immune responses by host cells (7, 8). One concern from these data is
that the exosome composition when evaluated by proteomics is qualitatively similar to
that of total Leishmania proteins, albeit with modest quantitative differences. Second,
Gluenz et al (2010) have proposed the existence of a ‘flagellar’ synapse in the parasites
orient their flagella such that the distal tip is in intimate contact with the phagolysosomal
membrane (6). Connecting these results is the observation of exosomes budding off of the
distal tip of Chlamydomonas flagella (9), suggesting a secretory role for this organelle.
Potentially antigen T17 represents an example of a stage-specific parasite ‘cargo’
delivered by the flagellar route. This will be pursued in the future by the Beverley
laboratory.
T18 epitope localizes to amastigote surface and a novel structure at the parasite’s
posterior pole
Figure 3 shows the localization of the antigen recognized by mAB T18 on amastigotes.
The parasite’s surface clearly is recognized by the antibody. In addition, most parasites
(78%, N = 187) have a region of intense staining on their posterior end, which is defined
as the end of the cell furthest from the kinetoplast DNA network (Figure 3A). 29% of
these parasites have an additional region of staining located between the parasite nucleus
and anterior pole (Figure 3B). In general, immunoEM studies yield results consistent with
what is seen by fluorescence microscopy, with antibody labeling present on the parasite
surface as well as labeling a ring of electron-dense material at the parasite’s posterior
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pole (Figure 3C & D). However, the T18 reactivity detected between the anterior pole
and the parasite nucleus that was seen by fluorescence microscopy was not detected by
immunoEM studies.
There are very few reports of organelles at the posterior end of L. major amastigotes. One
candidate for the structure recognized by mAB T18 is the “megasome”, a lysosome-like
organelle that has been described in New-World Leishmania species such as L.
amazonensis. This organelle, which is found near the posterior end of these parasites, has
been reported to degrade host MHC class II (10, 11). However, in electron micrographs,
amastigote megasomes do not resemble the electron-dense rings seen in our images, and
instead appear to be large, mostly open, vacuoles containing some electron dense material
(10). Thus the structure/region recognized by T18 may define a cellular structure that has
not been described previously.
Efforts to identify T17 and T18 antigens
The localization patterns of the antigens recognized by T17 and T18 are sufficiently
interesting to warrant studies directed towards the identification of the molecules
recognized by these antisera. One challenge is that Jaffe reported that these antisera do
not identify parasite molecules in western blotting (2). He did show that they were able to
immunoprecipitate several amastigote molecules, and from labeling studies inferred these
were proteins (2). Another challenge is the generation of sufficient amastigote lysate for
these studies, as isolation of lesion amastigotes from mice is costly, labor intensive, and
often results in substantial contamination with molecules of host origin. Unfortunately, L.
major does not give rise to culturable axenic amastigotes, despite efforts by our or other

204

laboratories. Previous work and preliminary studies I performed suggest that these
antibodies do not cross-react with amastigotes from other Leishmania species (2),
precluding the use of ‘axenic’ amastigotes from species such as L. tropica, L.
braziliensis, L. mexicana or L. donovani as a source of antigen. As such, an approach in
which the expression of the T17 and T18 antigens could be expressed by parasites in the
absence of host cells would be extremely beneficial.
To simulate conditions under which L. major might differentiate into amastigotes, we
diluted stationary-phase parasite cultures into commercially available RPMI. 24 hours
later, 40-60% of the parasites presented an amastigote-like morphology (round with no
visible flagella) and were reactive with T17 and T18 (Figure 4) and were “positive” for
some of the other amastigote differentiation markers described in Chapter 2 (data not
shown). Interestingly, the use of other media conditions which had previously be shown
to successfully to induce other Leishmania species such as L. donovani to differentiate
into amastigote-like forms and support their subsequent replication (11) was much less
successful at inducing T17 and T18 reactivity.
In collaboration with Igor Alameida’s lab at the University of Texas El Paso, these
conditions are being employed to generate large batches of cells expressing the T17 and
T18 antigens. Lysate from these parasites will be subjected to immunoprecipitations with
the two monoclonal antisera with the ultimate goal of antigen identification by MS. If
these experiments are successful, reverse genetic experiments will be conducted in our
lab to generate parasites that are unable to synthesize the molecules recognized by T17
and T18, which will be used as tools to help ascertain the function of these molecules in
the parasite life cycle.
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Figure legends
Figure 1. Localization of T17 reactvitiy. A-C) PEMs that had been infected for 3 days
with L. major were fixed as described in methods. A) Infected cells were stained with
rabbit antisera that recognize parasite histones and mouse mAB T17. Primary antibodies
were detected with Alexafluor488-conjugated anti-mouse antisera (green) and
Alexaflour555-conjugated anti-rabbit antisera (red). DNA was stained with Hoechst
33342 (blue). Images were captured using wide-field fluorescence microscopy, scale bar
represents 2 µm. B-C) Immuno-electron micrograph of infected PEMs stained with mAB
T17, in which T17-reactivity is indicated by silver granule deposition. Scale bar
represents 0.5 µm. Abbreviations: N = parasite nucleus, K = kinetoplast, A = flagellar
axoneme, P = posterior end.
Figure 2. T17 reactivity is seen in the cytoplasm of infected host cells. A) Confocal
micrograph of uninfected PEMs (left) or PEMs that had been infected for 3 days with L.
major. Samples were stained to detect parasite histones (red), the T17 antigen (green),
and DNA (blue). Bright green punctate staining is absent in uninfected PEMs, but present
in some infected PEMs. B) T17 reactivity is primarily on parasite flagella, but also
appears to exit phagolysosome and enter PEM cytoplasm at the flagellar distal tip. C) In
this image, T17 reactivity is primarily on the parasite flagella and surface (upper left hand
corner) but also within a membrane-bound compartment within PEM cytoplasm (arrow).
Scale bar represents 0.5 µm. Abbreviations for B and C: N = parasite nucleus, K =
kinetoplast, A = flagellar axoneme.
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Figure 3. Localization of T17 reactvitiy. A-C) PEMs that had been infected for 3 days
with L. major were fixed as described in methods. A) Infected cells were stained with
rabbit antisera that recognize parasite histones and mouse mAB T18. Primary antibodies
were detected with Alexafluor488-conjugated anti-mouse antisera (green) and
Alexaflour555-conjugated anti-rabbit antisera (red). DNA was stained with Hoechst
33342 (blue). Images were captured using wide-field fluorescence microscopy, scale bar
represents 2 µm. B) Confocal slice of a parasite as stained in (A) showing surface and
posterior labeling with mAB T18 (DNA labeling is not shown). Intracellular staining
between the nucleus and the anterior end of the parasite is also visible. Scale bar
represents 2 µm. C-D) Immuno-electron micrograph of infected PEMs stained with mAB
T18 in which T18 reactivity is detected by silver granule deposition. C and D) Zoomed-in
image of parasite posterior. Arrows indicate the amastigote-specific structure recognized
by mAB T18 and arrowheads indicate surface labeling. Scale bar represents 0.5 µm.
Abbreviations: N = parasite nucleus, K = kinetoplast, FP = flagellar pocket.
Figure 4. Induction of T17 and T18 reactivity in axenic culture. Representative images of
stationary-phase parasites that had been subjected to 37˚C in RPMI media for 24 hours
and stained with rabbit antisera raised against L. major histone proteins (red) and either
mAB T17 (left) or mAB T18 (right) shown in green. Scale bar represents 5 µM.
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